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ABSTRACT

Incidence, Risk Factors, and Prediction of Gastrointestinal and
Intracranial Bleeding in a Cohort of Older Veterans Prescribed Oral Anticoagulants
by
Angela L. Laurio

Advisor: Marianne (Mimi) C. Fahs, PhD, MPH

Objectives:
The objectives of this dissertation were to: (1) describe and compare the incidence and
odds of gastrointestinal and intracranial bleeding in veterans age 50 to 89 who were prescribed
warfarin, direct oral anticoagulants, or no oral anticoagulants; (2) identify risk factors for
gastrointestinal and intracranial bleeding among older veterans prescribed oral anticoagulants,
and to calculate the relative risk of bleeding over time through time-to-event analysis; and (3)
develop and compare models to predict risk of gastrointestinal and intracranial bleeding among
veterans age 50 to 89 who were prescribed warfarin or direct oral anticoagulants using traditional
and machine learning methods. These objectives were designed to assist healthcare organizations
meet goals for the reduction of anticoagulant-related adverse drug events.
Methods:
The three studies in this dissertation were carried out using a retrospective cohort design
and data from the Veterans Health Administration, American Community Survey, and National
Center for Health Statistics. In Study 1, incidence and odds of gastrointestinal and intracranial
iii

bleeding were calculated using the full cohort of subjects and compared across three groups:
those with no prescription for oral anticoagulants, those with a prescription for a direct oral
anticoagulant, and those with a prescription for warfarin. In Study 2, time-to-event analysis for
gastrointestinal or intracranial bleeding was conducted and independent risk factors identified for
subjects with a prescription for an oral anticoagulant (warfarin or direct oral anticoagulant). In
Study 3, predictive models were developed using traditional algorithms and machine learning
tools to predict risk of gastrointestinal or intracranial bleeding for subjects with a prescription for
oral anticoagulants.
The primary independent variable for all three studies was the subject’s prescription
category: no oral anticoagulant, warfarin, or direct oral anticoagulant. The primary dependent
variable was a dichotomous variable indicating the presence of an ICD-9 or ICD-10 code for
gastrointestinal or intracranial bleeding in the electronic health record. Diagnosis codes for
bleeding were associated with any type of clinical encounter, including inpatient admissions,
outpatient visits, or emergency room visits. Each subject’s index date was the date of the first
outpatient clinical encounter from October 1, 2010 to September 30, 2011 for the first study, and
the first OAC prescription date on or after October 1, 2010 for the second and third studies. The
cohort was drawn from patients with at least two primary care visits between October 1, 2010
and September 30, 2011 at a VISN-2 facility and assigned a primary care provider. Subjects
included in the study did not have a prescription for an oral anticoagulant in the six months prior
to index date.
Results:
Study 1 found that veterans who were not prescribed oral anticoagulants experienced an
average of 9 to 10 times the number of gastrointestinal bleeding events, and an average of 7 to 8
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times the intracranial bleeding events as would be expected in the general population. Using
either a no blackout or 5-day blackout period approach, this study found lower incidence rates
per 100 person-years for gastrointestinal and intracranial bleeding among veterans prescribed
oral anticoagulants than previous studies on both veterans and non-veterans. This study also
found lower odds of bleeding among veterans prescribed an oral anticoagulant than previous
studies; this was the case regardless of approach. Finally, an important finding of Study 1 was
the significant difference in incidence between the no blackout period and the 5-day blackout
period approaches.
Study 2 found that as the time from oral anticoagulant prescription increased, the
proportion of veterans age 50 and older who did not experience a gastrointestinal or intracranial
bleeding event after being prescribed warfarin was similar to those prescribed direct oral
anticoagulants. Findings were similar veterans with a diagnosis of atrial fibrillation. This finding
was reversed in subjects age 75 or older, but all of these differences were small and not
statistically significant. This study also found that prescriptions for antidepressants or statins
were the strongest risk factors for gastrointestinal or intracranial bleeding for all subjects, while
history of bleeding was the strongest risk factor for subjects with a diagnosis of atrial fibrillation
and for subjects age 75 or older.
Study 3 found that a logistic regression model using the traditional ORBIT algorithm
performed the best out of 12 models developed to predict gastrointestinal or intracranial bleeding
risk. A logistic regression model with a subset of five variables performed second best. Two
machine learning algorithms also performed fairly well in predicting bleeding risk: a lasso model
and a CART model. None of the models performed well in all five of the measures evaluated.
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Conclusions:
The greatest gains in preventing adverse drug events associated with oral anticoagulants
will likely be realized with increased sharing and use of electronic health data, and the ability to
discover predictive models that perform well on a variety of evaluation measures. Findings of the
three studies presented here were mixed in terms of being consistent with previous research, and
additional research is necessary to understand these differences. Reducing the occurrence of
gastrointestinal and intracranial bleeding following prescription of oral anticoagulants is an ongoing challenge, and while the studies presented in this dissertation shed some light on older
veterans and risk of gastrointestinal and intracranial bleeding, there are no easy answers to
solving this complex clinical problem.

vi

ACKNOWLEDGEMENTS
I am grateful for and have benefitted immeasurably from the knowledgeable and talented
members of my dissertation committee. My profuse thanks and gratitude to all of you: Dr. Mimi
Fahs for serving as my academic advisor for the last 6.5 years, for listening patiently to my many
and varying research ideas over the years, and guiding me to a coherent dissertation topic and
plan. Dr. Levi Waldron for your enthusiasm, optimism, tough questions, and willingness to work
with a student you had just met. Dr. Alexis Pozen for jumping in with both feet and giving
practical advice and guidance during this last year writing my dissertation. Dr. Ken Boockvar for
your patience and for sparking an interest in adverse drug events while collaborating at the
Bronx RHIO. And Dr. Zach Grinspan for always thinking outside the box and for propelling my
predictive modeling and R knowledge forward while an advisor for the Bronx RHIO.

I would also like to thank my husband, Eric, for his unwavering support through my doctoral
journey, tolerating all of my job, mood, and research changes, my long periods of self-imposed
isolation, for taking care of me (and our two cats), and for doing, literally, anything I asked, not
just willingly, but without complaint. I could not have done this without you.

Thank you to my mother, Alison, for always being supportive of my educational goals and for
helping me see the glass as half full, even when I was afraid it might not be.
Finally, I would be remiss if I didn’t thank my former bosses and mentors who helped me realize
this goal: Dr. Erik Langhoff and Linda Bund of the Bronx VA who encouraged me to study
Veterans and supported this research, Kathy Miller of the Bronx RHIO who assigned me to work
on predictive modeling when the guy who was supposed to do it never showed up, and David
Fletcher and Bill Perkins – my original predictive modeling gurus.
vii

DISCLOSURE STATEMENT
Author does not have anything to disclose.

viii

TABLE OF CONTENTS
Chapter 1: Introduction ................................................................................................................1
1.1 Adverse Drug Events are Common and Costly ..................................................................1
1.1.a Adverse Drug Events and Veterans ........................................................................1
1.2 Bleeding is the Most Common Adverse Drug Event Associated with Oral Anticoagulant
Use .......................................................................................................................................2
1.3 Warfarin is the Most Commonly Used Oral Anticoagulant ................................................2
1.4 Direct Oral Anticoagulants Were First Approved in 2010 ..................................................3
1.5 Bleeding Risk Algorithms Were Developed for Atrial Fibrillation Patients Taking Oral
Anticoagulants ....................................................................................................................4
1.6 Policies and Guidelines for Reducing Oral Anticoagulant-Related Bleeding ....................6
1.7 Machine Learning is a Tool for Adverse Drug Event Detection and Prediction ................7
1.8 The Method Used to Detect Adverse Drug Events has a Significant Impact on Findings .9
1.9 Overview of the Dissertation ..............................................................................................9
1.9.a Specific Aims ........................................................................................................10
1.9.b Innovation .............................................................................................................11
1.9.c Methods and Data Overview ................................................................................11
1.9.d Conceptual and Theoretical Framework ...............................................................15
1.9.e Hypotheses .............................................................................................................18
1.9.f Organization of the Dissertation ............................................................................19
Chapter 2: Incidence of Gastrointestinal and Intracranial Bleeding Among Older
Veterans .......................................................................................................................................28
2.1 Background .......................................................................................................................28
2.2 Data and Methods .............................................................................................................30
2.2.a Participants and Data Source ................................................................................30
2.2.b Study Variables .....................................................................................................30
2.2.c Approaches to Determining Bleeding Risk Exposure ..........................................31
2.2.d Analysis Approach .................................................................................................32
2.3 Results ................................................................................................................................33
2.4 Discussion ..........................................................................................................................37
2.5 Limitations .........................................................................................................................39
2.6 Conclusion .........................................................................................................................39
Chapter 3: Bleeding Risk Factors and Time-to-Event Analysis of Older Veterans
Prescribed Warfarin or Direct Oral Anticoagulants ................................................................48
3.1 Background .......................................................................................................................48
3.2 Data and Methods .............................................................................................................49
3.2.a Participants and Data Source ................................................................................49
ix

3.3
3.4
3.5
3.6

3.2.b Study Variables .....................................................................................................49
3.2.c Townsend Score ....................................................................................................50
3.2.d Analysis Approach .................................................................................................51
Results ................................................................................................................................52
Discussion ..........................................................................................................................55
Limitations .........................................................................................................................57
Conclusion .........................................................................................................................57

Chapter 4: Predicting Bleeding Risk in Older Veterans Prescribed Warfarin or Direct Oral
Anticoagulants Using Traditional and Machine Learning Methods ......................................64
4.1 Background .......................................................................................................................64
4.2 Data and Methods .............................................................................................................65
4.2.a Participants and Data Source ................................................................................65
4.2.b Study Variables .....................................................................................................66
4.2.c Analysis Approach .................................................................................................67
4.2.d Method for Evaluating Predictive Models .............................................................68
4.3 Results ................................................................................................................................69
4.4 Discussion ..........................................................................................................................72
4.5 Limitations .........................................................................................................................74
4.6 Conclusion .........................................................................................................................76
Chapter 5: Discussion ..................................................................................................................81
5.1 Overview of the Dissertation .............................................................................................81
5.2 Summary of Findings .........................................................................................................81
5.2.a Chapter 2 – Incidence and Odds of Gastrointestinal and Intracranial Bleeding ....81
5.2.b Chapter 3 – Bleeding Risk Factors and Time-to-Event Analysis ..........................83
5.2.c Chapter 4 – Predicting Bleeding Risk Using .........................................................84
5.3 Limitations .........................................................................................................................86
5.4 Synthesis and Implications ................................................................................................88
5.5 Conclusion and Recommendations for Future Research ..................................................89
Appendix 1. List of ICD-9 and ICD-10 Codes for Gastrointestinal and Intracranial
Bleeding as an Outcome ..............................................................................................................91
Appendix 2. List of ICD-9 and ICD-10 Codes for History of Bleeding Covariate.................96
Appendix 3. Decision Tree Model and Gains Tables ..............................................................107
REFERENCES ...........................................................................................................................110

x

LIST OF TABLES
1.1 Comparison of Variables Used in Traditional Bleeding Risk Algorithms ........................23
1.2 Study Variables and Definitions ........................................................................................24
2.1 Baseline Cohort Characteristics by OAC Prescription Category ......................................42
2.2 Event Type and OAC Category by Study Year for All Subjects .......................................44
2.3 Impact of OAC Category Classification ...........................................................................45
2.4 Comparison of Incidence Rate per 100 Person-years, No Blackout Period and 5-day
Blackout Period, All Subjects ............................................................................................45
2.5 Unadjusted Logistic Regression Model Using No Blackout Period, All Subjects, and
Stratified by Gender ...........................................................................................................45
2.6 Unadjusted Logistic Regression Model Using 5-day Blackout Period, All Subjects, and
46Stratified by Gender .......................................................................................................46
2.7 Adjusted Logistic Regression Model, No Blackout Period, All Subjects .........................46
2.8 Adjusted Logistic Regression Model, 5-day Blackout Period, All Subjects .....................47
3.1 Baseline Cohort Characteristics by OAC Prescription Category ......................................60
3.2 Time-to-Event Estimates for All Subjects .........................................................................61
3.3 Time-to-Event Estimates for Subjects with a Diagnosis of Atrial Fibrillation ..................61
3.4 Time-to-Event Estimates for Subjects Age 75 or Older ....................................................62
3.5 Cox Proportional Hazards Regression Final Model – All Subjects ...................................62
3.6 Cox Proportional Hazards Regression Final Model – Subjects with Atrial Fibrillation ...63
3.7 Cox Proportional Hazards Regression Final Model – Subjects Age 75 or Older ..............63
4.1 Predictive Model Evaluation Measures, Definitions, and Criteria ....................................77
4.2 Baseline Cohort Characteristics by OAC Prescription Category ......................................78
4.3 Models and Results ............................................................................................................79
4.4 Odds Ratios and Confidence Intervals for Logistic Regression Model with Subset of Best
Five Variables ....................................................................................................................80
A.3.1

Gains Table for ORBIT Model ............................................................................115

A.3.2

Gains Table for Logistic Regression Model with Subset of Best 5 Variables.....115

A.3.3

Lasso Machine Learning Model Variables and Odds Ratios...............................116
xi

LIST OF FIGURES
1.1 Prescription Trends for Warfarin and three DOACs (Dabigatran, Rivaroxaban, and
Apixaban), 2010 – 2014 .....................................................................................................21
1.2 Trends in Adverse Event Reporting to FDA for Warfarin and New OACs (Dabigatran,
Rivaroxaban, and Apixaban), 2010 – 2016 .......................................................................21
1.3 The Data Science Process ..................................................................................................22
1.4 A Vertical Fractal Illustrating the Multi-Level Concept of the Ecosocial Theory of
Epidemiology .....................................................................................................................22
2.1 Comparison of Annual Incidence of Gastrointestinal Bleeding, No Blackout Period and
5-day Blackout Period, 2011 – 2015, All Subjects ............................................................41
2.2 Comparison of Annual Incidence of Intracranial Bleeding, No Blackout Period and 5-day
Blackout Period, 2011 – 2015, All Subjects ......................................................................41
2.3 Whisker Plot Comparing Incidence Rates per 100 Person-Years by OAC Category and
Bleeding Event Type..........................................................................................................42
3.1 Kaplan-Meier and Survival (time-to-event) Function Curves for All Subjects (a, b),
Subjects with a Diagnosis of Atrial Fibrillation (c, d), and Subjects Age 75 or Older (e, f),
by OAC Category ..............................................................................................................59
4.1 Predicted Probability Plots and Lift Charts for the ORBIT Predictive Model and the
Logistic Regression with Subset of Five Best Variables Predictive Model ......................77
A.3.1

CART Machine Learning Algorithm Decision Tree Model ................................114

xii

Chapter 1
Introduction

1.1

Adverse Drug Events are Common and Costly
An Adverse Drug Event (ADE) is any unintended, undesirable, or harmful reaction

resulting from the use of a medication, including its intended use, errors in administration,
inappropriate prescribing, intentional or accidental poisoning, or abuse.1 According to the U.S.
Department of Health and Human Services (HHS), ADEs lead to approximately 1.3 million
emergency room and 3.5 million outpatient clinic visits, and 350,000 hospital admissions every
year.2 In addition, ADEs account for more than 60% of hospital post-discharge complications,
approximately half of which are preventable.2 The cost of ADEs is estimated at $76 billion per
year,3 with those occurring in the hospital costing $4.2 billion per year.2 The three medication
classes most commonly associated with ADEs are Anticoagulants, Diabetes Agents, and
Opioids.4 Oral Anticoagulants (OACs) are a subclass of anticoagulants, and are most commonly
prescribed for use outside of the hospital.4 Many ADEs associated with OACs can be prevented,
yet they remain a significant problem.4
1.1.a Adverse Drug Events and Veterans
Adverse drug events among veterans is a problem that has been documented in the
research literature since at least 1971,5 however only a few studies on ADEs have been published
since then that examined veterans as a population, despite an increasing focus on patient safety
within the Veterans Health Administration (VHA) – the healthcare delivery arm of the U.S.
Department of Veterans Affairs (VA). The 1971 study found a lower ADE incidence rate at the
single VA facility where the study was conducted compared to non-VA hospitals.5 A more
recent study using data from across the VA system found similar rates of ADEs compared to
1

non-VA hospitals.6 Another study found higher rates of ADEs in a VA hospital, but attributed
the higher number to the availability and quantity of electronic health data within the VA, which
allowed for identification of ADEs that might not have been identified at non-VA facilities
without an electronic health record system.7 A 2016 report by the Rand Corporation found
quality of care in VA facilities is as good as or better than private facilities,8 but the ability of VA
facilities to continue to make improvements in patient safety and quality are hindered by a lack
of recent studies of OAC-related ADEs in veterans. This gap gave rise to the desire to focus on
veterans as a population of interest for this dissertation.
1.2

Bleeding is the Most Common Adverse Drug Event Associated with Oral

Anticoagulant Use
Bleeding is the most common ADE associated with OAC use,9–12 with gastrointestinal
bleeding being the most common type, and intracranial bleeding the most likely to be
permanently disabling or fatal.13,14 Oral anticoagulants are often prescribed to patients with a
diagnosis of atrial fibrillation, deep vein thrombosis, pulmonary embolism, mechanical heart
valves, or following acute myocardial infarction to help prevent the formation of blood clots.12
Gastrointestinal and intracranial bleeding are the two outcomes of interest in the three studies
presented in Chapters 2, 3, and 4 of this dissertation.
1.3 Warfarin is the Most Commonly Used Oral Anticoagulant
Warfarin has been the most commonly used OAC for more than 60 years and is effective,
but increases the risk of bleeding.15 Each year approximately 15-20% of those taking warfarin
experience a bleeding event.16,17 Bleeding for those taking warfarin is approximately five times
higher than for those not taking OACs.18 In addition, bleeding associated with warfarin is higher
in the first month of use than when users are more experienced.17,19,20 From 2010 to 2014, 20 to
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30 million prescriptions for warfarin were written every year.21 The cost for a 30-day supply of
warfarin is approximately $10.22 Previous studies found incidence rates for gastrointestinal
bleeding of 3.71 per 100 person-years, and for intracranial bleeding of 0.67 per 100 person-years
among subjects prescribed warfarin.23 Another study found an incidence rate of 0.78 per 100
person-years for intracranial bleeding among veterans age 75 or older prescribed warfarin.24
Taking warfarin along with aspirin raises the risk of bleeding 2.5 times; taking warfarin and nonaspirin antiplatelet medications raises the risk of bleeding by 3 times.15 Patients taking warfarin
require frequent blood monitoring using the International Normalized Ratio (INR) test, with a
result considered to be in a therapeutic range if it is between 2 and 3 for most indications.25
Warfarin also has many food and drug interactions.25
1.4 Direct Oral Anticoagulants Were First Approved in 2010
Direct Oral anticoagulants (DOACs), first approved by the U.S. Food and Drug
Administration (FDA) in 2010,26 generally have a shorter acting time than warfarin, do not
require regular blood testing, and have fewer food and drug interactions.25 However, previous
studies have found that DOACs have a longer acting time in older adults.27 The three most
commonly prescribed DOACs are dabigatran, rivaroxaban, and apixaban.
Since the introduction of DOACs the number of annual warfarin prescriptions has fallen.
The number of annual prescriptions written for these three DOACs has increased every year
since 2010, even though they cost 30 to 40 times as much as warfarin. Dabigatran was the first
DOAC approved by the FDA on October 19, 2010.26 Since being approved there have been
approximately two to three million prescriptions for dabigatran every year.21 The cost for a 30day supply of dabigatran is approximately $359.22 Rivaroxaban was approved by the FDA on
July 1, 2011.26 Since being approved there have been approximately two to three million
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prescriptions for rivaroxaban every year.21 The cost for a 30-day supply of rivaroxaban is
approximately $397.22 Apixaban was approved by the FDA on December 28, 2012.26 There were
approximately 1.3 million prescriptions for apixaban in 2014,21 the only year for which data were
available. The cost for a 30-day supply of apixaban is approximately $406.22 Figure 1.1 shows
prescription trends for warfarin and these three DOACs from 2010 to 2014.
A recent retrospective cohort study found the risk of gastrointestinal bleeding was lower
in patients prescribed DOACs versus those prescribed warfarin, though in patients older than 75
this finding was reversed, and gastrointestinal bleeding risk was higher for those using DOACs
than warfarin.27 Two recent meta-analyses had contradictory findings: one found the risk of
gastrointestinal bleeding was increased for those taking DOACs versus warfarin when the
indication was acute myocardial infarction or prevention of venous thrombosis;9 while the other
found lower rates of major and fatal bleeding in patients taking DOACs.28 Studies published
using clinical trials data show that half of the clinical trials for DOACs excluded patients who
had risk factors or conditions predisposing them to bleeding – such as concomitant use of aspirin
or non-aspirin antiplatelet medications – making the patient populations studied less like those
seen by providers in usual clinical practice.9,27,29 Warfarin and the three DOACs discussed above
(dabigatran, rivaroxaban, and apixaban) are the exposures of interest for the three studies
presented in Chapters 2, 3, and 4.
1.5 Bleeding Risk Algorithms Were Developed for Atrial Fibrillation Patients Taking Oral
Anticoagulants
Older adults with a diagnosis of atrial fibrillation are those most likely to be taking
OACs, and this patient population has been well studied. Several bleeding risk algorithms were
developed over the last two decades based on studies of cohorts of atrial fibrillation patients.

4

Four of the more recent and comparatively studied bleeding risk algorithms and the variables
they include are listed in Table 1.1. These four algorithms – HAS-BLED, ATRIA, QBLEED,
and ORBIT – were used as comparators in the study presented in Chapter 4.
The Area Under the Curve (AUC) is a statistical measure used to assess how well an
algorithm predicts whether subjects will experience a specified outcome.30 The higher the AUC
the better the algorithm is at predicting the outcome. Benchmark ranges for AUC used in
previous research categorized AUC as: poor if < 0.6, fair if 0.6 to 0.69, good if 0.7 to 0.79, very
good if 0.8 to 0.89, and excellent if 0.9 to 1.0.31
A study comparing HAS-BLED to other bleeding risk algorithms found HAS-BLED had
a higher AUC (ranging from 0.60-0.66) than the four other algorithms to which it was
compared.32 The original study describing HAS-BLED as a convenient and effective predictor of
bleeding risk found an AUC range of 0.72-0.91.24 Both of these studies focused on patients with
atrial fibrillation participating in studies related to interventions for their diagnosis (rather than
OAC use), so that may account for the varying results. A recent study comparing a newer
bleeding risk algorithm, ORBIT, to the HAS-BLED and ATRIA algorithms found ORBIT had
an AUC of 0.67, compared to 0.64 for HAS-BLED and 0.66 for ATRIA.33 This study used a
completely different population for validating the risk models, and found the AUCs decreased by
approximately 0.05 for each of the three models when applied to the new datasets.33 The HASBLED algorithm is recommended as the preferred method for determining bleeding risk
according to the European Society of cardiology34 and the American College of Cardiology.35
The ability to use existing algorithms to assign risk can save healthcare organizations many
hours of work in developing their own.
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The studies that generated the algorithms in Table 1.1 used clinical and administrative
data, with limited demographic, lifestyle, and socioeconomic variables. The QBLEED algorithm,
based on studies done in the U.K., found Townsend score – a population measure of relative
material deprivation – was a predictor for bleeding risk.34 None of these studies used machine
learning in the development of algorithms. Machine learning and Townsend score are discussed
in more detail in sections 1.7 Machine Learning, and 1.9.d. Methods Overview.
1.6 Policies and Guidelines for Reducing Oral Anticoagulant-Related Bleeding
Reducing harm to patients taking anticoagulants has been a Joint Commission Patient
Safety Goal (PSG) for hospitals, ambulatory care, and long-term care since 2008.36 Performance
elements associated with this goal include baseline INR testing, following evidence-based
guidelines, and having and following written facility policies related to anticoagulant
management.37 A randomized controlled trial from Canada published five years prior to the PSG
found patients taking OACs managed by anticoagulation clinics had an INR Therapeutic Time in
Range (TTIR) of 82% versus 76% for those patients managed by family medicine doctors.38
Despite these and similar findings in other studies, many patients taking anticoagulants are not
managed in specialized clinics.39
In July 2015 the VHA published a new policy on anticoagulation therapy management.40
This policy requires providers with patients taking OACs to perform periodic risk assessments of
these patients, including assessing bleeding risk and calculating TTIR for patients prescribed
warfarin.40 Computer-based tools are currently being implemented that will allow VHA
pharmacists to automatically calculate a patient’s TTIR, but a method for assessing risk has yet
to be developed or implemented.
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The National Action Plan for Adverse Drug Event Prevention is a set of goals published
by HHS in 2014 that aim to reduce the number of ADEs experienced by patients in all healthcare
settings.4 Anticoagulants are included as a class of medications targeted in the plan.4 The Federal
Interagency Steering Committee and Workgroups for ADEs published targets and measures for
the goals in September 2017.2 The target for anticoagulants is a 10% reduction in inpatient and
outpatient ADEs by 2020.41 Although these goals and targets for reduction are not considered
law, there is an incentive for healthcare organizations to meet them. Measurement of
anticoagulant-related ADEs that occur in hospitals will be included in the Hospital-Acquired
Condition Reduction Program, which beginning October 1, 2017, called for hospitals with a
Hospital-Acquired Condition score above a certain threshold to be penalized with a 1% Medicare
payment reduction.42 There is no similar incentive for outpatient, home health, or long-term care,
even though most OAC prescriptions are for patients who are not hospitalized.38,39 The Hospital
Acquired Condition policy does not apply to VA hospitals.
Reaching the goals set forth by The Joint Commission, VHA, and National Action Plan
will require increased sharing, use, and integration of electronic health data – not just from
electronic health records, but also from insurance claims, pharmacy benefit managers, public
health departments, and regional health information exchanges. The amount of available
healthcare data is growing at a rate of 48% per year, faster than the 40% per year in other sectors
of the economy.43 In order to use this growing volume of data in meaningful ways, the use of
automated tools and processes will be crucial.
1.7 Machine Learning is a Tool for Adverse Drug Event Detection and Prediction
Machine learning is a subfield of computer science concerned with the development and
implementation of computerized algorithms that improve with experience,44 or automatically
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improve by analyzing data.45,46 Machine learning algorithms, or tools, improve by “learning”
from the data they are given to analyze. This learning process is categorized as supervised or
unsupervised.45,46 In supervised machine learning the data contain both inputs (characteristics,
features, risk factors) and outputs (outcomes of interest),45,46 so the machine learning algorithm is
“trained” in looking for the specified outcome. In practice this is done by using part of the data
for training and part for validation.47 The machine learning algorithm is first run using the
training dataset, exposing the outcome of interest to the algorithm, so for each record in the data
the algorithm knows whether or not the outcome was present. Next the algorithm is run on the
remaining portion of the data, or a completely new dataset, with the outcome masked from the
algorithm. The algorithm makes a prediction about each subject – was the outcome present? The
machine learning algorithm results can then be compared to actual outcomes to determine how
well the algorithm performed. Unsupervised machine learning algorithms do not contain an
outcome of interest, so the algorithm relies solely on inputs in order to determine associations in
the data.45,46 Unsupervised machine learning is best for describing the relationships between data,
while supervised learning is better for making predictions.48 The math underlying machine
learning algorithms includes linear and logistic regression, and Bayesian probabilistic models45–
47

– methods familiar to health researchers. Some nonlinear machine learning algorithms use

hidden computational layers that can contain sigmoidal, planar, or other non-probabilistic
functions to make predictions;47 these are sometimes referred to as “black-box” algorithms.45 An
advantage of using machine learning tools based on familiar statistical methods is the ability to
interpret the results.45,47 Machine learning algorithms can process larger datasets and more
combinations of data than can be handled using traditional statistical methods,49 including
datasets too large for or with processing requirements beyond the capability of a single
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computer. Machine learning could enable the analysis of more and different types of data to
detect bleeding among those prescribed OACs, and to predict who is at greatest risk of bleeding.
1.8 The Method Used to Detect Adverse Drug Events has a Significant Impact on Findings
The traditional method for collecting data about ADEs has been through voluntary
reporting. Hospitals and healthcare systems collect data on ADEs reported by providers and
staff. The FDA hosts two web-based reporting portals for consumers, healthcare providers,
manufacturers, researchers and research participants to report ADEs.50,51 Medical diagnosis
codes – the International Classification of Diseases 9th and 10th Revisions (ICD-9 and ICD-10)
include codes specifically for diagnosing a condition related to an ADE, but they are
underutilized.4 Research shows voluntary reporting of ADEs results in underestimation of the
true count of events. A study comparing the incidence of inpatient ADEs detected using three
different methods at the same facility found 0.7% of inpatients experienced an ADE when using
voluntary reports, 9.6% using a computer monitoring program, and 13.3% using chart reviews.52
Similarly, studies examining electronic health record data versus other means of detecting
adverse drug events consistently found electronic health record data identified six to 10 times
more ADEs than voluntary reporting systems,52–54 but identified approximately 20% fewer than
manual chart review.52 Figure 1.2 shows the number of adverse drug event reports submitted to
the FDA from 2010 through 2016 for warfarin, dabigatran, rivaroxaban, and apixaban.51 These
voluntary reports were a fraction of a percent of annual prescriptions. As the U.S. population
continues to age, more people will take more prescription medications.4 Until voluntary reporting
improves to the point that all or most ADEs are captured, all available electronic data should be
used to help reduce the occurrence of ADEs.
1.9 Overview of the Dissertation
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Currently there is no automated, free, non-proprietary model to predict bleeding risk
among veterans prescribed OACs using readily available data from electronic health records.
Prior research has focused on cohorts of patients based on diagnoses, and were conducted
primarily in non-VA settings. Despite involvement in developing the National Action Plan for
ADE Prevention and publishing a policy requiring monitoring and risk assessment of patients
prescribed OACs, there are only a few studies on bleeding among veterans prescribed
OACs.5,6,29,55–57 Veterans are a sizable population in the U.S., totaling about 20 million, or just
over 6% of the U.S. population as a whole, with about 9 million enrolled in the VA health care
system.58 Understanding the incidence and risk factors for gastrointestinal and intracranial
bleeding among older veterans, and being able to predict bleeding risk could save lives, prevent
hospitalizations, reduce healthcare costs, and contribute to reaching Patient Safety and National
Action Plan goals, as well as complying with VHA policy.
In order to meet these needs, three studies were conducted in conjunction with this
dissertation using a cohort of veterans age 50 to 89 who received outpatient clinic services at a
Veterans Integrated Service Network- (VISN-) 2 facility (New York and New Jersey) between
10/01/2010 and 09/30/2015, with the following aims:
1.9.a Specific Aims
Aim 1: Describe the cumulative incidence and incidence rates of gastrointestinal and intracranial
bleeding in a cohort of older veterans. Stratify cumulative incidence and incidence rates by
subjects prescribed warfarin, DOACs, and no OACs, and use logistic regression to compare the
odds of gastrointestinal and intracranial bleeding between these three groups.
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Aim 2: Determine the time course of gastrointestinal and intracranial bleeding risk for older
veterans prescribed OACs as time taking OACs increases, by identifying risk factors using a
retrospective cohort design and time-to-event analysis.
Aim 3: Develop, evaluate, and select models to predict risk of gastrointestinal and intracranial
bleeding for older veterans prescribed OACs using machine learning tools, and compare model
performance to the HAS-BLED, ATRIA, ORBIT, and QBLEED algorithms.
1.9.b Innovation
The three studies completed for this dissertation involved a retrospective cohort drawn
from a clinical and administrative database of electronic health record data, rather than one
compiled for clinical trials or other research purposes, resulting in a design that was closer to a
population-based study (where the population was veterans) and was comprised of subjects who
were more like the patients providers see in usual clinical practice. These three studies provide
an update to previous research that was conducted prior to FDA approval of DOACs and the
development of the ATRIA, QBLEED, and ORBIT bleeding risk algorithms. The study
presented in Chapter 4 was also the first to use machine learning tools to develop bleeding risk
models, and to compare machine learning models to traditional risk scores (HAS-BLED,
ATRIA, QBLEED, and ORBIT). Finally, this research is the first to involve a multi-facility
cohort of veterans to produce automated, free, non-proprietary models that can help both VA and
non-VA healthcare organizations meet ADE prevention goals.
1.9.c Methods and Data Overview
The three research aims of this dissertation were accomplished with a retrospective
cohort design using data from the Veterans Health Administration. The VHA is the largest
integrated healthcare system in the U.S. and is comprised of 144 hospitals and 1,211 outpatient
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clinics.59 It was the first system in the country to use a common electronic health record with
system-wide information exchange.60 Data in the VHA corporate data warehouse dates back to
October 1, 1998 and includes inpatient, outpatient, and emergency room encounter dates,
diagnoses, lab test dates and results, prescription medication names, doses, and dates filled,
demographics, 5-digit Zip code, and sociodemographic variables such as marital status, and
insurance type. The VA delivered healthcare services to over 6.5 million Veterans in 2014,61
including over 90 million outpatient visits and 700,000 inpatient admissions.61 The VISN-2
network provides healthcare services to more than 500,000 veterans living in 76 counties in New
York, New Jersey, and Pennsylvania.62
Aim 1 analyses were conducted using the full cohort of subjects, while the analyses for
Aims 2 and 3 were conducted using only subjects with a prescription for an OAC. The primary
independent variable was the subject’s OAC prescription category: no OAC, warfarin, or DOAC.
The primary dependent variable was a dichotomous variable indicating the presence of an
ICD-9 or ICD-10 code for gastrointestinal or intracranial bleeding in the electronic health record
(see Appendix 1 for a list of included ICD-9 and ICD-10 codes). The codes used in all three
studies were the same, replicating code lists from previous research.27,34,63,64 Diagnosis codes for
bleeding were associated with any type of clinical encounter, including inpatient admissions,
outpatient visits, or emergency room visits. Each subject’s index date was the date of the first
outpatient clinical encounter from October 1, 2010 to September 30, 2011 for the first study, and
the first OAC prescription date on or after October 1, 2010 for the second and third studies. The
cohort was drawn from patients with at least two primary care visits between October 1, 2010
and September 30, 2011 at a VISN-2 facility and assigned a primary care provider. The cohort
was selected in this way because subjects with two or more outpatient encounters and an
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assigned primary care provider were more likely to receive regular care through the VA, and also
have the most complete clinical and administrative data for analysis.
A diagnosis of atrial fibrillation is the most common reason why patients are prescribed
OACs,32 and risk of atrial fibrillation increases after age 50,32 therefore the age range for
inclusion in the study was 50 to 89. Cohort exclusion criteria were: (1) a prescription for an OAC
in the six months prior to index, in order to include only subjects with an incident OAC
prescription, or the first prescription after a long period of non-use. This six month exclusion was
consistent with prior research.34 And (2) a Continental U.S.-based 5-digit Zip code, in order to
allow for augmentation of the VHA dataset with data from the National Center for Health
Statistics and American Community Survey (ACS).
The National Center for Health Statistics (NCHS) assigns a percent rural designation to
counties in order to allow researchers to study the effects of urban versus rural residence.65 The
cohort of veterans who were the subjects of the studies included in this dissertation resided
primarily in New York, New Jersey, and Pennsylvania, all states that include both very urban
and very rural areas. There were too many counties represented in the cohort to use county as a
categorical variable, but the use of the percent rural value assigned by NCHS allowed the
inclusion of a variable to account for geographic location. The relationship between health
outcomes and geography is well documented,66 so inclusion of a geographic variable portrayed a
more holistic view of subjects. Subjects were matched by county of residence to the 2013 NCHS
percent rural designation – a continuous value ranging from zero to 100.
The ACS replaced the Census Bureau long-form survey in 2010, and is the main means
for collecting demographic and social data on the U.S. population.67 Each subject’s 5-digit Zip
code of residence was matched to the 2012 ACS data on the following five Zip code-level
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variables: (1) percent living in overcrowded conditions (defined as more than one occupant per
room), (2) percent unemployment, (3) percent with no access to a car, (4) percent of renteroccupied dwellings, and (5) median household income.67 The first four of these ACS variables
were used to calculate the Townsend score, and were represented as continuous numeric values
from zero to one.
The Townsend score is a population measure that estimates material deprivation,68 and
has been used in the U.K. for many years to estimate relative deprivation and measure
correlations between deprivation and health status.34,69 The Townsend score is an unweighted
sum of measures 1-4 above. The Townsend score has been shown to correlate well with healthrelated measures such as overall health, depression, and long-term illness.69 Another study found
that median household income approximated deprivation as well as the Townsend score,70 and
studies from both the U.K. and U.S. found the Townsend score may be less indicative of relative
deprivation in urban than rural communities.69–72 Zip code-level median household income was
included as a study variable in order to provide another estimate of socioeconomic status, since
many of the veterans in the cohort lived in urban areas, Townsend score may not be an accurate
measure of relative deprivation. A priori it was unknown whether Townsend score or median
household income would be a significant factor associated with gastrointestinal and intracranial
bleeding in the study cohort.
There are several methods for calculating Therapeutic Time in Range (TTIR) using
results of INR lab tests of subjects prescribed warfarin. Three of the most common methods used
in clinical trials are fraction of INRs, cross-sectional, and Rosendaal.73 Fraction of INRs in range
is calculated by dividing the number of INRs in the target therapeutic range by the total number
of INRs during the time period of study.73 The cross-sectional method is calculated in a manner
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similar to fraction of INRs but for a designated day, plus or minus 7 days.73 Rosendaal linear
interpolation is a longitudinal method incorporating person-time, and uses a designated interval
between tests and a maximum number of days to carry the interpolated value forward in time, in
the absence of another test result.73 The main disadvantages of the Rosendaal method are the
assumptions made about test interval and carry forward time, which likely will not apply to all
patients in the calculation.
Few published studies on warfarin and bleeding described how TTIR was calculated,
however most clinical trials used the Rosendaal method.74,75 The only study identified that
compared the three most common methods on the same population found the fraction of INRs
and cross-sectional methods produced similar results, but the Rosendaal method produced
significantly lower TTIR results for two-, three-, and six-month intervals.73 For the purposes of
this dissertation, TTIR was calculated for each subject who was prescribed warfarin using the
fraction of INRs method for each year of the study. The reason for using fraction of INRs was to
simplify calculations, and because TTIR is a variable for only one of the bleeding risk score
comparators (HAS-BLED) for the study presented in Chapter 4.
1.9.d Conceptual and Theoretical Frameworks
The Data Science process (Figure 1.3) is a conceptual framework that influenced the
goals and process of this dissertation. Data Science is an approach that combines statistics,
machine learning, computer programming, data visualization, and domain expertise to provide
information for decision making and produce data products.76 The first step of the Data Science
process is collecting or obtaining data, followed by data processing. What makes this different
from traditional approaches to research is that the data scientist uses computer programming –
usually Structured Query Language (SQL) or Python – to collect and process large amounts of
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electronic data.76 Instead of requesting a dataset or finding an existing dataset, the data scientist
extracts the data from the source, and in the course of doing so makes decisions about processing
– constructing variables as categorical, numeric, dichotomous, etc. For the studies presented in
this dissertation, SQL was used to select the study cohort from the VA Corporate Data
Warehouse according to the criteria in section 1.9.c Methods and Data Overview. An initial SQL
query returned the cohort with demographic variables and index date. Subsequent queries were
written to join comorbidities, prescriptions, outcomes, and TTIR calculations to the cohort
dataset. This iterative approach to building the cohort dataset with multiple SQL queries was
necessary due to computer processing limitations and VA rules for accessing the data warehouse.
The aims of the dissertation research built on one another. Aim 1 sought to define the
scope of the problem of gastrointestinal and intracranial bleeding among older veterans. Aim 2
sought to determine risk factors and time-to-event for gastrointestinal and intracranial bleeding.
These provided the foundation for Aim 3, the completion of which produced a data product in
the form of a free, non-proprietary model that can be automated and is available to any
healthcare facility to use for self-monitoring, benchmarking, and quality improvement, with the
goal of predicting risk of gastrointestinal or intracranial bleeding following prescription of an
OAC. The more healthcare organizations use the predictive model the greater the opportunity for
aggregate data collection, creation of a feedback loop, and new data for ongoing refinement of
models as they degrade.
Data Science is a relatively new discipline that has been successfully applied to finance,
marketing, Internet services (e-mail spam filters and consumer recommendations), and genomic
and cancer research.76 Data Science as a discipline often focuses on the discovery of previously
unknown or novel relationships within large datasets, whereas classical biomedical statistics
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tends to be hypothesis driven. The dissertation research applied the Data Science process –
including data collection, synthesis, predictive modeling, and independent validation of a
predictive model – to the problem of gastrointestinal and intracranial bleeding among veterans to
facilitate compliance with patient safety goals and directives.
This dissertation was also informed by the Ecosocial Theory of Epidemiology,77
especially in terms of variables selected for inclusion in the studies. Ecosocial theory, a
multilevel approach, seeks to uncover the causes of population health disparities through the
examination of variables interacting on multiple levels and how they create an ecosystem that
influences health.78 Ecosocial theory seeks to explore how membership in various groups leads
to population patterns of health, and because its view of society is dynamic, it is a model that can
scale down to the genomic level or up to a global health view.78 Figure 1.4 uses a vertical fractal
to illustrate the multi-level concept of Ecosocial Theory. To draw an example from the
dissertation, a subject could hypothetically have a genetic biomarker predisposing him to certain
types of cancer, making him a member of a group of subjects with that genetic biomarker. He
may also have a diagnosis of congestive heart failure, making him a member of a group of
subjects with that diagnosis. He is also a member of various groups based on his individual
characteristics, including those related to socioeconomic status, such as race, insurance coverage,
or disability category. He is also a member of various groups based on the characteristics of the
five-digit Zip code where he lives, and he is a member of a group of veterans. Being a part of
these different groups influences health in different ways, but membership in these groups can
change as individual, neighborhood-level, or even veteran-level characteristics change. When
viewed in this way the social determinants of health become less a final explanation of health
outcomes (poor health status due to race or socioeconomic status), and more of a starting point
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for exploring the societal and environmental conditions that led to the poor health outcome in a
particular population. Ecosocial Theory encourages questions that require a multi-level
examination of social and environmental factors that impact health,77,78 such as how a policy
decision impacted a racial group and contributed to a health outcome. Other examples include
hospital ownership, pollution, and de facto segregation. Ecosocial Theory, in conjunction with
the literature, influenced the selection of variables for the dissertation studies. A list of study
variables is shown in table 1.2.
1.9.e Hypotheses
Aim 1: Describe the cumulative incidence and incidence rates of gastrointestinal and intracranial
bleeding among older veterans. Stratify cumulative incidence and incidence rates by subjects
prescribed warfarin, DOACs, and no OACs, and use logistic regression to compare the odds of
gastrointestinal and intracranial bleeding between these three groups.
Hypotheses:
(1) Cumulative incidence and incidence rates of gastrointestinal and intracranial
bleeding will be comparable to previous studies.
(2) Cumulative incidence and incidence rates of gastrointestinal and intracranial
bleeding will be higher among subjects prescribed DOACs compared to those
prescribed warfarin.
Aim 2: Determine the time course of gastrointestinal and intracranial bleeding risk for older
veterans prescribed OACs as time taking OACs increases, by identifying risk factors using a
retrospective cohort design and time-to-event analysis.
Hypotheses:

18

(1) Variables estimating socioeconomic deprivation – Townsend score and
median household income by Zip code – will be significant risk factors for
gastrointestinal and intracranial bleeding.
(2) Being prescribed an OAC for a longer period of time will be associated with
increased risk of gastrointestinal or intracranial bleeding.
Aim 3: Develop, evaluate, and select models to predict risk of gastrointestinal and intracranial
bleeding for older veterans prescribed OACs using machine learning tools, and compare model
performance to the HAS-BLED, ATRIA, ORBIT, and QBLEED algorithms.
Hypotheses:
(1) One or more algorithms produced using machine learning will accurately
predict gastrointestinal and intracranial bleeding, with a sensitivity of 80% or
greater and a positive predictive value of 75% or greater.
(2) Machine learning algorithms will perform better than the traditional
algorithms to which they are compared (HAS-BLED, ATRIA, ORBIT, and
QBLEED) at predicting risk of gastrointestinal and intracranial bleeding.
1.9.f Organization of the Dissertation
The dissertation is organized into five chapters, including this introductory chapter,
Chapter 1. The study presented in Chapter 2 describes the cumulative annual incidence per 1,000
veterans who experienced gastrointestinal and intracranial bleeding stratified by OAC
prescription category (no OAC, warfarin, or DOAC), incidence rate per 100 person-years for the
5-year study period by OAC prescription category, and odds of experiencing a gastrointestinal or
intracranial bleeding event by OAC category using logistic regression (Aim 1). The study
presented in Chapter 3 identifies risk factors for gastrointestinal and intracranial bleeding, and
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calculates the relative risk of bleeding over time for veterans with an OAC prescription using
time-to-event analysis (Aim 2). The study presented in Chapter 4 compares models to predict
risk of gastrointestinal and intracranial bleeding for veterans prescribed an OAC using logistic
regression and machine learning tools (Aim 3). Chapter 5 presents a summary and synthesis of
the findings from the studies presented in Chapters 2 through 4, discussion of the policy and
public health implications of the findings, and recommendations for future research.
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Figure 1.1. Prescription Trends for Warfarin and Three DOACs (Dabigatran, Rivaroxaban, and
Apixaban), 2010 – 2014.21 Date in parentheses is the date of FDA approval.26

Figure 1.2. Trends in Adverse Event Reporting to FDA for Warfarin and Three DOACs
(Dabigatran, Rivaroxaban, and Apixaban), 2010 – 2016.79
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Figure 1.3 The Data Science Process.76

Figure 1.4. A Vertical Fractal Illustrating the Multi-Level Concept of the Ecosocial Theory of
Epidemiology.78
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Table 1.1. Comparison of Variables Used in Traditional Bleeding Risk Algorithms.
Algorithm 
Risk Factor
Age
Age > 65
Age >= 75
Alcohol Use/Abuse
Anemia
Antidepressants
Antiplatelet Medication
Atrial Fibrillation
Cancer
Carbamazepine^
Congestive Heart Failure
Corticosteroids
Diabetes
Drug Use/Abuse
Ethnicity
Female Gender
History of Bleeding
History of Stroke
Hypertension
Liver or Renal Disease
Low Platelet Count
NSAIDS*
Phenytoin^
Smoker
TTIR < 60%**
Townsend score
Venous
Thromboembolism

HAS-BLED

ATRIA

QBLEED

ORBIT

(Pisters, 2010)

(Singer, 2013)

(Hippisley-Cox, 2014)

(O'Brien, 2015)

X
X

X
X

X

X
X

X

X
X
X
X
X
X
X

X

X
X
X
X
X
X
X
X

X
X
X
X

X
X
X
X
X
X

X

X

X
X
X

*NSAIDS are nonsteroidal anti-inflammatory drugs. ^Carbamazepine and phenytoin are
anticonvulsant medications. **TTIR is therapeutic time in range for an International Normalized
Ratio blood test for those taking warfarin.
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Table 1.2. Study Variables and Definitions.
Variable Name

Type and Definition
Primary Independent Variable

Values

Categorical- describes the subject's first OAC
prescription after the index date

Warfarin
DOAC
None

Dichotomous- subject had a prescription for warfarin
on/after index date (descriptive only; not used for
modeling)

Yes/No

Dabigatran

Dichotomous- subject had a prescription for this DOAC
on/after index date (descriptive only; not used for
modeling)

Yes/No

Rivaroxaban

Dichotomous- subject had a prescription for this DOAC
on/after index date (descriptive only; not used for
modeling)

Yes/No

OAC Category

Warfarin

Apixaban

Bleeding Event

Dichotomous- subject had a prescription for this DOAC
on/after index date (descriptive only; not used for
modeling)
Primary Dependent Variable
Dichotomous- subject had a diagnosis code for bleeding
after the index date

Age

Categorical- type of bleeding the subject experienced
(descriptive only; not used for modeling)
Other Explanatory Variables
Demographic
Continuous- subject's age in years at index

Age >= 75
Gender

Dichotomous- subject's age was greater than or equal
to 75 years at index
Subject's reported gender

Bleeding Type

Marital Status

Subject's reported marital status

Race/Ethnicity

Subject's combined reported race/ethnicity
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Yes/No

Yes/No
Gastrointestinal
Intracranial
None

Integer
Yes/No
Male/Female
Married (or separated)
Not Married (never
married, divorced,
widowed, unk/missing)
White Non-Hispanic
Non-White (American
Indian or Alaska Native,
Asian, Black Non-Hispanic,
Hispanic or Latino, Multiple
races, Native Hawaiian or
other Pacific Islander,
unk/missing)

Smoker
Obese

Subject's reported smoking status
Dichotomous- subject had BMI >= 30%

Yes (current smoker)
No (former or never
smoker, unk/missing)
Yes/No (unk/missing)

Months of
Observation

Continuous- number of months the subject contributed
to the study, from index date to censor date (bleeding
event, death, or end of study)

Integer

Time-to-Event

Continuous- number of days from the subject's first
OAC prescription date to censor date (bleeding, death,
or end of study)
Socioeconomic

Numeric

Disability

Dichotomous- the subject had a Military ServiceConnected Disability

Yes/No

Insurance Coverage

Dichotomous- the subject had health insurance
(private, Medicare, or Medicaid)

Yes/No

Exempt from VA
Copayment

Dichotomous- the subject was not required to pay an
out-of-pocket copayment for VA health services

Yes/No

Continuous- unweighted sum of percent unemployed,
percent overcrowding, percent with no vehicle, and
percent renter-occupied at the 5-digit Zip code level

Numeric

Townsend Score*
Median Household
Income*

Percent Rural**

Continuous- at the 5-digit Zip code level
Geographic
Continuous- percent of geographic area in county of
residence considered rural
Co-prescriptions

Numeric

Numeric

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

NSAIDS

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Steroids

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Statins

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Antidepressants

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Amiodarone

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Carbamazepine

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Aspirin
Non-Aspirin
Antiplatelet
Medication

25

Phenytoin

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Antifungals

Dichotomous- subject had a prescription for this
medication at any time prior to index

Yes/No

Number of
Prescriptions

Continuous- count of active prescriptions at index
Comorbidities

Integer

Diabetes

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Congestive Heart
Failure

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Hypertension

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Atrial Fibrillation

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Chronic Kidney
Disease

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Liver Disease

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Chronic Pancreatitis

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Stroke

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

Pulmonary Embolism

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

Deep Vein Thrombosis

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

Cancer

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Esophageal Varices

Dichotomous- subject had an ICD-9 or ICD-10 code for
this disease at any time prior to index

Yes/No

Ulcer

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

Acute Myocardial
Infarction

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

Alcohol Abuse

Dichotomous- subject had an ICD-9 or ICD-10 code for
this condition at any time prior to index

Yes/No

History of Bleeding

Low Platelet Count

Dichotomous- subject had an ICD-9 or ICD-10 code for
bleeding at any time prior to index
Blood Tests and Medical Procedures
Dichotomous- subject had a lab result value <
150,000/mcl at any time prior to index
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Yes/No

Yes/No

Heart Valve
Replacement
HAS-BLED
ORBIT
ATRIA

Dichotomous- subject had ICD-9 or ICD-10 procedure
code or CPT code any time prior to index
Bleeding Risk Scores
Sum of points based on algorithm
Sum of points based on algorithm
Sum of points based on algorithm

*Data source: American Community Survey
**Data source: National Center for Health Statistics
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Yes/No
Integer
Integer
Integer

Chapter 2
Incidence of Gastrointestinal and Intracranial Bleeding Among Older Veterans

2.1

Background
Adverse drug events affect 5-10% of inpatients,1,80–82 1-3% of emergency room

patients,1,83,84 and 25-35% of clinic outpatients.52,85 Adverse drug events increase morbidity and
cost $76 billion per year.3 One of the drug classes most commonly associated with adverse drug
events is OACs, the use of which can cause life-threatening adverse events such as
gastrointestinal and intracranial bleeding.4,14,34 OACs are often prescribed to patients with atrial
fibrillation, deep vein thrombosis, pulmonary embolism, mechanical heart valves, or following
acute myocardial infarction to help prevent the formation of blood clots and further morbidity.12
Gastrointestinal bleeding is the most common adverse outcome associated with OAC use, and
intracranial bleeding is the most likely to be permanently disabling or fatal.14,86
Warfarin has been the most commonly used OAC for more than 60 years and is effective,
but puts patients at risk for bleeding.15 Previous studies found incidence rates for gastrointestinal
bleeding of 3.71 per 100 person-years, and for intracranial bleeding of 0.67 per 100 person-years
among subjects prescribed warfarin.27 Another study found an incidence rate of 0.78 per 100
person-years for intracranial bleeding among veterans age 75 or older prescribed warfarin.56
Direct OACs (DOACs), first approved by the U.S. Food and Drug Administration in
2010, require less time to reach a therapeutic blood level after administration than warfarin, and
do not require regular blood testing.25 Studies have shown that DOACs remain in the
bloodstream longer in older adults.27 A recent retrospective cohort study found the risk of
gastrointestinal bleeding was lower in patients prescribed DOACs versus those prescribed
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warfarin, though in patients older than 75 this finding was reversed.27 The same study found an
incidence rate of 1.66 and 4.1 per 100 person-years for gastrointestinal bleeding among those
prescribed rivaroxaban and dabigatran (two DOACs), respectively.27 Two recent meta-analyses
had contradictory findings: one found the risk of gastrointestinal bleeding was increased for
those taking DOACs versus warfarin when the indication was acute myocardial infarction or
prevention of venous thrombosis;9 while the other found lower rates of major and fatal bleeding
in patients with atrial fibrillation or acute venous thromboembolism who were given DOACs.28
Studies published using clinical trials data showed half of clinical trials of DOACs excluded
patients who had risk factors or conditions predisposing them to bleeding, making the patient
populations studied less like those seen by providers in usual clinical practice.9,28,29,87
Many studies describing incidence or risk of bleeding associated with OACs are limited
to subjects with a specific diagnosis, such as atrial fibrillation or venous thromboembolism. In
addition, previous studies defined bleeding differently in terms of diagnoses or clinical criteria
(lab values or a blood transfusion) to be met in order for a bleeding event to be counted in the
outcome. These factors make it difficult to compare results across studies. No recent studies
examining a broad category of bleeding or comparing incidence of bleeding in veterans
prescribed warfarin versus DOACs or no OACs were identified.
The objectives of this study were to describe and compare the cumulative incidence,
incidence rates, and odds of gastrointestinal and intracranial bleeding in veterans age 50 to 89
who were prescribed warfarin, DOACs, or no OACs using a retrospective cohort design. This
study was approved by the U.S. Department of Veterans Affairs (VA), Veterans Integrated
Service Network- (VISN-) 2 Institutional Review Board, Research and Development Committee,
and Safety Committee.
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2.2

Data and Methods

2.2.a Participants and Data Source
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code, at
least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30,
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based
Outpatient Clinic in Pennsylvania.62 The first visit on or after October 1, 2010 was used as the
index date for when the subject joined the cohort. The cohort was comprised of 131,135 subjects.
One subject was excluded due to having a non-U.S. based Zip code, and 384 were excluded for
having a prescription for an OAC in the six months prior to index, resulting in 130,750 patients
included in the analyses. The study period was October 1, 2010 through September 30, 2015, for
a total of five Federal fiscal years – the common reporting cycle for the VA. The 130,750
subjects contributed 614,196 person-years of observation time to the study. Nearly 96%
(n=124,946) of subjects were followed until the end of the study.
2.2.b Study Variables
The primary dependent variable was the presence of an ICD-9 or ICD-10 Code for
gastrointestinal or intracranial bleeding (see Appendix 1), recorded in the dataset as dichotomous
variables (one for each type of bleeding event). The primary independent variable was a
categorical variable for OAC prescription (warfarin, DOAC, or no OAC). Direct OACs included
in the study were dabigatran, rivaroxaban, and apixaban. Subjects included in the cohort did not
have a prescription for any OAC in the six months prior to their index date. Other explanatory
variables were insurance coverage; prescriptions for aspirin, non-aspirin antiplatelet medications,
or non-steroidal anti-inflammatory drugs (NSAIDS); and diagnosis of hypertension, chronic
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kidney disease, liver disease, history of stroke or bleeding (see Appendix 2 for a list of ICD-9
and ICD-10 codes), congestive heart failure, diabetes, atrial fibrillation, deep vein thrombosis,
pulmonary embolism, cancer, ulcer, esophageal varices, acute myocardial infarction, alcohol
abuse, or heart valve replacement – all as dichotomous variables. Age and number of
prescriptions at index date were included as continuous variables, and gender, body mass index
(BMI), marital status, smoking status, service-connected disability, exempt from VA copayment
(an indicator of low income), and race/ethnicity were included as categorical variables.
2.2.c

Approaches to Determining Bleeding Risk Exposure
There was no standard research practice identified for determining when bleeding risk

exposure begins after OAC prescription fill or first dose date. This was true of clinical trials as
well. Previous studies used zero, 3, 4, 5, or 7-days.63,86–90 Despite research showing that new
users of warfarin have a higher risk of bleeding in the first 30 days of use,19,20 many clinical trials
only included subjects who had been prescribed warfarin for at least 180 days and had stable
International Normalized Ratio levels.29,33,35 Other studies counted all bleeding events after a
minimum of 1 dose of an OAC, regardless of type (warfarin or DOAC).19,20,88,89 Due to this lack
of consistency, two approaches were used to determine if subjects were classified as having an
OAC prescription at the time of a bleeding event.
The first approach was to count any OAC prescription that preceded a bleeding event,
regardless of OAC type, even if the bleeding event was the next day. This approach is referred to
in the results as “no blackout period.” The second approach was to classify subjects as having a
prescription for an OAC at the time of a bleeding event only if the prescription preceded the
bleeding event by five or more days, referred to in the results as “5-day blackout period.”
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The five day time period was chosen based on the fact that warfarin takes 2 – 7 days to
reach therapeutic blood levels.11,91 In contrast, DOACs are effective in much shorter time
periods, generally less than 24 hours from the first dose.25 The OAC prescription date used in the
current study was the date when the filled prescription was given to the subject, so while this
should provide a date and time close to the administration of the first dose (lacking that exact
date and time), there may still be a time lag.
2.2.d Analysis Approach
Cumulative incidence of gastrointestinal and intracranial bleeding was calculated for each
year of the study to compare groups by OAC category, and to examine trends over time using
both the no blackout and 5-day blackout period approaches. Cumulative incidence was
calculated using the following formula:92
Cumulative incidence =

Number of bleeding events
Number of subjects

The incidence rate per 100 person-years over the 5-year study period was calculated for
all subjects comparing the no blackout and 5-day blackout period approaches using the following
formula:92
Incidence Rate =

Number of bleeding events
Person-time

Odds of experiencing a bleeding event were calculated using logistic regression for both
approaches. Due to their small numbers, gastrointestinal and intracranial bleeding events were
grouped together for regression analyses. The formula for logistic regression with multiple
predictors is:47
𝑝

𝑙𝑜𝑔 (1−𝑝) = 𝛽0 + 𝛽1 𝑥1 + ⋯ + 𝛽𝑛 𝑥𝑛
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Unadjusted regression models were developed for all subjects and stratified by gender
using both approaches; then adjusted regression models were developed for all subjects using
both approaches, and covariates significant at the 0.05 level are shown. Analyses were completed
using R version 3.4.1 and Microsoft Excel 2013.
2.3

Results
The cohort included 130,750 subjects. Ninety-six percent (n=126,232) of subjects were

male, 53% (n=69,938) were married, 84% (n=110,409) had insurance, and 75% (n=98,007) were
White Non-Hispanic (3.37% missing). Only four percent (n=5,010) of subjects had a new
prescription for an OAC during the study period, while 10% (n=13,060) had a new or renewed
prescription for aspirin, 6% (n=8,041) for non-aspirin antiplatelet medications, and 31%
(n=40,423) for NSAIDS. Thirty-five percent (n=45,873) of the cohort never smoked. Fifteen
percent (n=19,366) were obese (BMI > 30), but 66% (n=86,661) of the cohort were missing
height, weight, or both, so BMI could not be calculated. Chronic conditions were common in the
cohort: 83% (n=108,975) had a diagnosis of hypertension, 41% (n=53,905) had a diagnosis of
diabetes, 10% (n=12,505) had a diagnosis of congestive heart failure, 30% (n=39,096) had a
diagnosis of cancer, and 36% (n=47,634) had a diagnosis indicating prior bleeding (see
Appendix 2 for a list of ICD-9 and ICD-10 codes). Thirteen percent of the cohort (n=17,390) had
a diagnosis of atrial fibrillation. Table 2.1 further describes the cohort.
Fewer than six percent of subjects experienced a bleeding event (n=7,250) or died (n=41)
during the study period. Table 2.2 shows the number of subjects and events over the five years of
the study by OAC category. Table 2.3 shows how the approach to OAC classification had an
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impact on category assignment among study subjects. This helps to illustrate the differences in
the findings using the two approaches that follow.
Figure 2.1 compares the cumulative incidence of gastrointestinal bleeding per 1,000
veterans by OAC category and year using the two approaches. Figure 2.2 compares the annual
incidence of intracranial bleeding per 1,000 veterans by OAC category and year using the two
approaches. Using the no blackout period approach subjects followed an expected pattern with
cumulative gastrointestinal bleeding incidence being lowest among subjects with no OAC
prescription. Subjects with a prescription for DOACs fell in the middle of the three groups in
terms of cumulative incidence using this approach, and subjects with a prescription for warfarin
had the highest cumulative incidence. Using a 5-day blackout period, subjects with a prescription
for DOACs had lower cumulative incidence of gastrointestinal bleeding than subjects with no
OAC prescription for the first four years of the study, and cumulative intracranial bleeding
incidence among subjects prescribed DOACs was lower than subjects prescribed no OACs in
years 1, 2, 3, and 5 using this approach. Both approaches illustrate a trend in increased
cumulative incidence of gastrointestinal bleeding among veterans prescribed OACs over the five
years of the study.
Subjects prescribed no OACs had low cumulative incidence of intracranial bleeding
using both approaches, and cumulative incidence remained relatively flat over the five years of
the study. Using the no blackout period approach subjects prescribed warfarin had cumulative
intracranial bleeding incidence that increased and decreased in alternating years, but was similar
in the last year of study to the first year of study. Subjects prescribed DOACs also had an up and
down pattern, but ended the five years higher than the first or third years of the study. Using a 5day blackout period subjects prescribed warfarin had a spike in cumulative intracranial bleeding
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incidence in year three, and increased incidence over years 1, 2, and 4. Subjects prescribed
DOACs had relatively flat cumulative incidence of intracranial bleeding, and in years 1, 3, and 5,
had lower cumulative incidence than subjects prescribed no OACs.
Table 2.4 shows a comparison of incidence rates per 100 person-years between the no
blackout and 5-day blackout period approaches. The time period for these rates is the five years
of the study. The incidence rate for either type of bleeding per 100 person-years using no
blackout period was 1.13 for subjects not prescribed OACs, 1.82 for subjects prescribed DOACs,
and 2.70 for subjects prescribed warfarin. The incidence rate for either type of bleeding per 100
person-years using a 5-day blackout period was 1.17 for subjects not prescribed OACs, 0.72 for
subjects prescribed DOACs, and 1.61 for subjects prescribed warfarin. Using no blackout period
the rate per 100 person-years for gastrointestinal bleeding for subjects prescribed no OACs was
1.01, and for intracranial bleeding was 0.12. For subjects prescribed DOACs the rate per 100
person-years for gastrointestinal bleeding was 1.53, and for intracranial bleeding was 0.29. For
subjects prescribed warfarin the rate per 100 person-years for gastrointestinal bleeding was 2.36,
and for intracranial bleeding was 0.34. Using a 5-day blackout period the rate per 100 personyears for gastrointestinal bleeding for subjects prescribed no OACs was 1.04, and for intracranial
bleeding was 0.13. For subjects prescribed DOACs the rate per 100 person-years for
gastrointestinal bleeding was 0.62, and for intracranial bleeding was 0.10. For subjects
prescribed warfarin the rate per 100 person-years for gastrointestinal bleeding was 1.42, and for
intracranial bleeding was 0.19. Figure 2.3 visualizes the incidence rates listed in Table 2.4, using
a whisker plot to illustrate the differences in rates using the two approaches, indicating statistical
significance for the pairs of rates (no blackout and 5-day blackout by bleeding type and OAC
category) where confidence intervals do not overlap.
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Tables 2.5 and 2.6 show the results of unadjusted logistic regression models using the no
blackout period and 5-day blackout period approaches for all subjects and stratified by gender.
The unadjusted logistic regression model with no blackout period found subjects prescribed
DOACs had 1.66 the odds of gastrointestinal or intracranial bleeding compared to subjects
without an OAC prescription, and subjects prescribed warfarin had 2.53 the odds of
gastrointestinal or intracranial bleeding compared to subjects without an OAC prescription. This
was true for male subjects as well, but the findings for female subjects was not statistically
significant. The unadjusted logistic regression model with a 5-day blackout period found subjects
with a prescription for DOACs had 0.62 the odds of gastrointestinal or intracranial bleeding
compared to subjects without an OAC prescription, and subjects prescribed warfarin had 1.42 the
odds of gastrointestinal or intracranial bleeding compared to subjects without an OAC
prescription. These findings were similar among male subjects, but for female subjects the
results were not statistically significant.
Tables 2.7 and 2.8 show the results of logistic regression models adjusted for the
covariates listed in Table 2.1. Results are shown for all subjects, along with covariates that were
significant at the 0.05 level. The adjusted logistic regression model using no blackout period
found subjects prescribed warfarin had 1.47 the odds of gastrointestinal or intracranial bleeding
compared to subjects without an OAC prescription, and subjects prescribed DOACs had 1.30 the
odds of gastrointestinal or intracranial bleeding compared to subjects without a prescription for
OACs. Other statistically significant covariates were history of bleeding, esophageal varices,
stroke, ulcer, and a concurrent prescription for aspirin or non-aspirin antiplatelet medications.
The adjusted logistic regression model using a 5-day blackout period found subjects prescribed
warfarin had 0.72 the odds of gastrointestinal or intracranial bleeding compared to subjects

36

without a prescription for OACs, and subjects prescribed DOACs had 0.42 the odds of
gastrointestinal or intracranial bleeding compared to subjects without an OAC prescription.
Other statistically significant covariates were similar to the adjusted model with no blackout
period.
2.4

Discussion
This study produced four main findings. First, gastrointestinal and intracranial bleeding

was not common in this cohort of older veterans (5.54%). Second, the approach taken (no
blackout period versus 5-day blackout period) had a significant impact on the results of
cumulative incidence, incidence rate, and odds calculations. Third, cumulative incidence of
gastrointestinal and intracranial bleeding among subjects prescribed no OACs was higher than
expected. Fourth, incidence rates per 100 person-years for gastrointestinal and intracranial
bleeding among subjects prescribed DOACs or warfarin was lower than previous studies.
Gastrointestinal bleeding in the general population is estimated at 25 to 100 events per
100,000 people (depending on the bleeding site),93 while intracranial bleeding in the general
population is estimated at 12 to 15 events per 100,000 people of all ages, and as high as 350
events per 100,000 in the elderly with hypertension.94 The subjects in this study who were not
prescribed OACs experienced an average of 9 to 10 times the number of gastrointestinal bleeding
events, and an average of 7 to 8 times the intracranial bleeding events as would be expected in
the general population. Unfortunately, no studies were identified that focused on gastrointestinal
or intracranial bleeding in veterans who were not prescribed OACs, so there is not a good
historical comparison.
Using both the no blackout and 5-day blackout period approaches this study found lower
incidence rates per 100 person-years for gastrointestinal and intracranial bleeding among
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subjects prescribed OACs than in previous studies on non-veteran populations.14,27,56 This study
also found lower odds of bleeding among subjects prescribed OACs (using both approaches)
than a previous meta-analysis of randomized, controlled trials involving non-veteran
populations.9
An important finding of this study was the difference in results between the no blackout
period and the 5-day blackout period approaches. Using no blackout period, subjects prescribed
warfarin who experienced bleeding events prior to the time when warfarin had likely reached a
therapeutic level were counted as having the outcome, and therefore the cumulative incidence,
incidence rate, and odds of bleeding among subjects prescribed warfarin using this approach
appeared higher than it probably was. Using a 5-day blackout period, subjects prescribed
DOACs who experienced bleeding events during the blackout period were not counted as having
the outcome, even though DOACs reach a therapeutic level much faster than warfarin, so the
cumulative incidence, incidence rate, and odds of bleeding among subjects prescribed DOACs
using this approach appeared lower than it probably was. Both approaches had the potential of
introducing classification bias into a portion of the study population in terms of the OAC
category to which they were assigned. A better approach to blackout period could be a hybrid of
the two compared here: to use no blackout period for subjects prescribed DOACs, and a 5-day
blackout period for subjects prescribed warfarin. Approached in this way, there would be no
statistically significant difference in incidence rate per 100 person-years between those
prescribed DOACs and warfarin. The implications of this finding are that studies should be
examined carefully to determine how bleeding events were counted before extrapolating results
to different populations and implementing interventions in clinical practice, as the results of
studies using different blackout periods are not directly comparable.
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This study found a higher cumulative incidence of gastrointestinal and intracranial
bleeding among subjects not prescribed any OACs than previous studies on the general
population, but found lower incidence rates per 100 person-years, and lower odds of both
gastrointestinal and intracranial bleeding among subjects prescribed warfarin or DOACs than
previous studies.
2.5

Limitations
This study had several limitations. Data used in this study came from a clinical and

administrative database, and did not include non-VA insurance claims or pharmacy benefit data,
so services and prescriptions obtained outside the VA healthcare system were not included,
although every effort was made to include those veterans who appeared to receive care at the VA
as their primary site of care. Subjects for this study were chosen based on outpatient utilization
rather than on hospitalization and subsequent OAC prescription. It’s possible that using a posthospitalization cohort would have yielded different results. The subjects in this study were
overwhelmingly male, so it’s uncertain how applicable findings from this study are to female
veterans. The subjects included in this study primarily lived in New York and New Jersey, and
regional differences in demographics may limit the generalizability of findings to other parts of
the United States. This study didn’t include different OAC doses, changes in dose, or changes
from one OAC to another. Finally, this study only examined the impact of two different blackout
periods to determine OAC prescription category, and it is possible that other blackout periods
would result in different findings, although this study may be the first to identify how differences
in the blackout period used impact study results.
2.6

Conclusion
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This study used two different approaches to compare the cumulative incidence, incidence
rate, and odds of gastrointestinal and intracranial bleeding over five years among a cohort of
veterans prescribed no OACs, DOACs, and warfarin, who received care at New York and New
Jersey VA healthcare facilities. The blackout period used to categorize subjects in terms of OAC
prescription had a significant impact on results. Cumulative incidence of gastrointestinal and
intracranial bleeding among those not prescribed any OACs was higher than previous studies on
the general population, and may be the first to examine veterans specifically. Using different
blackout periods for OACs based on their pharmacotherapeutic properties would provide a less
biased comparison of incidence rates and odds of bleeding across categories. Future research
should focus on uncovering associations that would explain the much higher cumulative
incidence of bleeding among veterans not prescribed OACs, and the lower incidence rates and
odds of bleeding among veterans prescribed warfarin and DOACs.
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Figure 2.1. Comparison of Cumulative Incidence of Gastrointestinal Bleeding, No Blackout
Period and 5-day Blackout Period, All Subjects (n=130,750) by Year.

Figure 2.2. Comparison of Cumulative Incidence of Intracranial Bleeding, No Blackout Period
and 5-day Blackout Period, All Subjects (n=130,750) by Year.
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Figure 2.3. Whisker Plot Comparing Incidence Rates per 100 Person-years Over Five Years
(2011 – 2015) by OAC Category and Bleeding Event Type.

KEY: Red dot = incidence rate per 100 person-years; Blue squares = 95% confidence intervals
No BO = no blackout period; 5D BO = 5-day blackout period
GI Bldg = gastrointestinal bleeding; ICR Bldg = intracranial bleeding

Table 2.1. Baseline Cohort Characteristics by OAC Prescription Category.
Variable
Number of Subjects
Age (mean (sd))
Gender = Male (%)
Marital Status (%)
Never Married
Divorced
Married
Separated
Unknown/Missing
Widowed
Percent Service-Connected
Disability (%)
None
10-30%

No OAC
125,740
70.68 (9.86)
121,325 (96.5)
16,808 (13.4)
26,428 (21)
67,458 (53.6)
5,235 (4.2)
93 (0.1)
9,718 (7.7)

DOAC
1,040
75.54 (8.62)
1,024 (98.5)

Warfarin
3,970
71.76 (8.97)
3883 (97.8)

89 (8.6)
194 (18.7)
618 (59.4)
31 (3)
0 (0)
108 (10.4)

486 (12.2)
978 (24.6)
1,862 (46.9)
235 (5.9)
2 (0.1)
407 (10.3)

p-Value
<0.001
<0.001
<0.001

<0.001
73,866 (58.7)
15,396 (12.2)
42

639 (61.4)
113 (10.9)

2,271 (57.2)
393 (9.9)

40-60%
70-100%
Insurance Coverage (%)
Aspirin (%)
Antiplatelet Medication (%)
NSAIDS (%)
Exempt from VA Copayment (%)
No
Unknown/Missing
Yes

10,673 (8.5)
25,805 (20.5)
105,884 (84.2)
12,090 (9.6)
7,419 (5.9)
38,788 (30.8)

60 (5.8)
228 (21.9)
980 (94.2)
126 (12.1)
123 (11.8)
254 (24.4)

292 (7.4)
1,014 (25.5)
3,545 (89.3)
844 (21.3)
499 (12.6)
1,381 (34.8)

115,249 (91.7)
115 (0.1)
10,376 (8.3)

927 (89.1)
1 (0.1)
112 (10.8)

3,655 (92.1)
2 (0.1)
313 (7.9)

Number of Prescriptions
(mean (sd))
Race/Ethnicity (%)
White Non-Hispanic

3.54 (2.43)

3.92 (2.26)

3.91 (2.75)

94,059 (74.8)

857 (82.4)

3,091 (77.9)

American Indian or Alaska
Native
Asian
Black Non-Hispanic
Hispanic or Latino
Multiple Races

362 (0.3)
279 (0.2)
19,643 (15.6)
5,929 (4.7)
778 (0.6)

5 (0.5)
2 (0.2)
93 (8.9)
28 (2.7)
9 (0.9)

12 (0.3)
3 (0.1)
584 (14.7)
159 (4)
26 (0.7)

408 (0.3)
4,282 (3.4)

7 (0.7)
39 (3.8)

6 (0.2)
89 (2.2)

<0.001
<0.001
<0.001
<0.001
0.038

<0.001
<0.001

Native Hawaiian or Other
Pacific Islander
Unknown/Missing
Smoking Status (%)
Never Smoked
Current Smoker
Former Smoker
Unknown/Missing
Diabetes (%)

44,085 (35.1)
25,762 (20.5)
54,762 (43.6)
1,131 (0.9)
51,324 (40.8)

490 (47.1)
131 (12.6)
414 (39.8)
5 (0.5)
498 (47.9)

1,298 (32.7)
748 (18.8)
1,815 (45.7)
109 (2.7)
2,083 (52.5)

<0.001

Congestive Heart Failure (%)
Hypertension (%)
Atrial Fibrillation (%)
Chronic Kidney Disease (%)
Liver Disease (%)
History of Stroke (%)
Pulmonary Embolism (%)
Deep Vein Thrombosis (%)
Cancer (%)
Peptic Ulcer (%)
Esophageal Varices (%)
History of Bleeding (%)

10,952 (8.7)
104,341 (83)
13,952 (11.1)
16,433 (13.1)
16,090 (12.8)
10,865 (8.6)
1,503 (1.2)
5,352 (4.3)
37,326 (29.7)
5,496 (4.4)
654 (0.5)
45,078 (35.9)

265 (25.5)
973 (93.6)
891 (85.7)
170 (16.3)
115 (11.1)
157 (15.1)
81 (7.8)
146 (14)
353 (33.9)
52 (5)
2 (0.2)
459 (44.1)

1,288 (32.4)
3,661 (92.2)
2,547 (64.2)
887 (22.3)
590 (14.9)
732 (18.4)
594 (15)
1,194 (30.1)
1,417 (35.7)
229 (5.8)
27 (0.7)
2,097 (52.8)

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.129
<0.001

<0.001
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Body Mass Index (BMI) (%)
Normal (18.5-24.9)
Obese (>= 30)
Overweight(25-29.9)
Underweight (< 18.5)

6,977 (5.5)
18,447 (14.7)
16,780 (13.3)
205 (0.2)

25 (2.4)
130 (12.5)
103 (9.9)
0 (0)

166 (4.2)
789 (19.9)
460 (11.6)
7 (0.2)

<0.001

Unknown/Missing
Heart Valve Replacement (%)

83,331 (66.3)
2,125 (1.7)

782 (75.2)
29 (2.8)

2,548 (64.2)
262 (6.6)

<0.001

Acute Myocardial Infarction (%)
Alcohol Abuse (%)

3,687 (2.9)
45,078 (35.9)

60 (5.8)
459 (44.1)

333 (8.4)
2,097 (52.8)

<0.001
<0.001

61,873.23
(24,754.72)

69,969.73
(26,432.72)

60,779.36
(23,745.97)

<0.001

Median Household Income for
Zip Code (mean (sd))

Table 2.2. Event Type and OAC Category by Study Year for All Subjects (n=130,750).
Event Type
OAC Category
Death
No OAC
DOAC
Warfarin
End of Study
No OAC
DOAC
Warfarin

2011

2012

2013

2014

1
1
0
0
0
0
0
0

0
0
0
0
0
0
0
0

1
1
0
0
0
0
0
0

3
2
0
1
0
0
0
0

2015
36
35
0
1
123,459
118,789
1,004
3,666

Gastrointestinal
Bleeding
No OAC
DOAC
Warfarin

1,480
1,461
0
19

1,283
1,250
1
32

1,179
1,101
6
72

1,262
1,197
5
60

1,256
1,153
19
84

6,460
6,162
31
267

Intracranial
Bleeding
No OAC
DOAC
Warfarin
Total

160
158
0
2
1,641

128
124
1
3
1,411

166
154
1
11
1,346

141
195
131
183
2
1
8
11
1,406 124,946

790
750
5
35
130,750
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Total
41
39
0
2
123,459
118,789
1,004
3,666

Table 2.3. Impact of OAC Category Classification.
OAC
Category
DOAC
No OAC
Warfarin
Total

No Bleeding
&
No Blackout
1,010
118,813
3,677
123,500

No Bleeding &
5-day
Blackout
Change
1,004
-6
118,828
15
3,668
-9
123,500
0

Yes
Bleeding &
No Blackout
94
6,637
519
7,250

Yes Bleeding &
5-day Blackout Change
36
-58
6,912
275
302
-217
7,250
0

Table 2.4. Comparison of Incidence Rates per 100 Person-years Over 5 Years (2011-2015), No
Blackout Period and 5-day Blackout Period, All Subjects (n=130,750).

Category
No OAC
Gastrointestinal
Bleeding
Intracranial
Bleeding
DOAC

No Blackout Period
Rate per
Sum of
100 PersonEvents
PersonYears
(n)
Years
(95% CI)
1.13
6,637 589,841.43 (1.10, 1.15)

5-day Blackout Period
Rate per
Sum of
100 PersonEvents
PersonYears
(n)
Years
(95% CI)
1.17
6,912 590,440.41 (1.14, 1.20)

1.01
(0.98, 1.03)

1.04
(1.02, 1.07)

5,928

13,452.50

709

1,759.76

94

5,162.46

0.12
(0.11, 0.13)
1.82
(1.48, 2.22)
1.53
(1.22, 1.90)

Gastrointestinal
Bleeding

79

206.37

Intracranial
Bleeding

15

43.30

Warfarin

519

Gastrointestinal
Bleeding

453

Intracranial
Bleeding

66

6,162

13,893.56

750

1,845.47

36

5,016.16

0.13
(0.12, 0.14)
0.72
(0.51, 0.98)

31

118.29

0.62
(0.43, 0.87)

5

14.14

19,192.54

0.29
(0.17, 0.47)
2.70
(2.48, 2.94)

302

18,739.86

0.10
(0.04, 0.22)
1.61
(1.44, 1.80)

1,143.21

2.36
(2.15, 2.59)

267

790.23

1.42
(1.26, 1.60)

162.60

0.34
(0.27, 0.43)

106.05

0.19
(0.13, 0.26)
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Table 2.5. Unadjusted Logistic Regression Model Using No Blackout Period, All Subjects, and
Stratified by Gender. No OAC prescription was the comparator.
All Subjects
(n=130,750)
(Intercept)
DOAC
Warfarin

Estimate Std. Error p-Value Odds Ratio
95% CI lower
95% CI upper
-2.885
0.013
0.056
0.054
0.057
0.000
0.510
0.109
0.000
1.666
1.338
2.049
0.927
0.049
2.527
2.295
2.776
0.000
45

Males
(n=126,232)
(Intercept)
DOAC
Warfarin
Females
(4,518)
(Intercept)
DOAC
Warfarin

-2.893
0.511
0.936

0.013
0.110
0.049

0.000
0.000
0.000

0.055
1.668
2.550

0.054
1.336
2.314

0.057
2.056
2.805

-2.673
0.727
0.688

0.061
0.758
0.327

0.000
0.338
0.036

0.069
2.068
1.991

0.061
0.324
0.992

0.078
7.449
3.623

Table 2.6. Unadjusted Logistic Regression Model Using 5-day Blackout Period, All Subjects,
and Stratified by Gender. No OAC prescription was the comparator.
All Subjects
(n=130,750)
(Intercept)
DOAC
Warfarin
Males
(n=126,232)
(Intercept)
DOAC
Warfarin
Females
(n=4,518)
(Intercept)
DOAC
Warfarin

Estimate
-2.844
-0.484
0.347

Std. Error
0.012
0.170
0.061

p-Value
0.000
0.004
0.000

Odds Ratio
0.058
0.616
1.415

95% CI lower
0.057
0.434
1.253

95% CI upper
0.060
0.847
1.593

-2.852
-0.520
0.353

0.013
0.175
0.062

0.000
0.003
0.000

0.058
0.595
1.424

0.056
0.414
1.259

0.059
0.824
1.605

-2.659
0.713
0.223

0.061
0.758
0.399

0.000
0.347
0.577

0.070
2.040
1.249

0.062
0.319
0.520

0.079
7.345
2.543

Table 2.7. Adjusted Logistic Regression Model, No Blackout Period, All Subjects (n=130,750).
No OAC prescription was the comparator.
Variable
(Intercept)
History of Bleeding
Esophageal Varices
Male
History of Stroke
Ulcer
Warfarin
Aspirin
DOAC

Estimate
-5.068
4.487
0.543
0.481
0.432
0.407
0.384
0.298
0.263

Std.
Error
0.158
0.084
0.109
0.066
0.037
0.046
0.058
0.037
0.120
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pValue
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.028

Odds
Ratio
0.006
88.890
1.720
1.617
1.540
1.503
1.468
1.347
1.300

95% CI
lower
0.005
75.969
1.380
1.428
1.441
1.370
1.308
1.250
0.991

95% CI
upper
0.008
105.555
2.118
1.847
1.663
1.640
1.647
1.444
1.589

Unknown Race/Ethnicity
Antiplatelet Medication
Congestive Heart Failure
Acute Myocardial Infarction
NSAIDS
Black Non-Hispanic Race
Current Smoker
Cancer
Number of Prescriptions
Age
Married
Unknown BMI

0.218
0.217
0.206
0.178
0.175
0.160
0.106
0.070
-0.021
-0.026
-0.085
-0.160

0.081
0.047
0.040
0.058
0.027
0.033
0.035
0.028
0.007
0.002
0.039
0.057

0.008
0.000
0.000
0.002
0.000
0.000
0.003
0.013
0.002
0.000
0.029
0.005

1.243
1.242
1.228
1.195
1.191
1.173
1.112
1.073
0.980
0.974
0.918
0.852

1.053
1.133
1.137
1.056
1.128
1.101
1.038
1.017
0.967
0.971
0.853
0.766

1.448
1.363
1.327
1.323
1.253
1.254
1.191
1.135
0.992
0.977
0.993
0.958

Table 2.8. Adjusted Logistic Regression Model, 5-day Blackout Period, All Subjects
(n=130,750). No OAC prescription was the comparator.
Variable
(Intercept)
History of Bleeding
Esophageal Varices
Male
History of Stroke
Ulcer
Aspirin
Antiplatelet Medication
Unknown Race/Ethnicity
Congestive Heart Failure
Pulmonary Embolism
Atrial Fibrillation
Acute Myocardial Infarction
NSAIDS
Black Non-Hispanic Race
Current Smoker
Cancer
Number of Prescriptions
Age
Married
Unknown BMI
Warfarin
DOAC

Estimate
-5.051
4.491
0.536
0.487
0.433
0.404
0.321
0.235
0.228
0.223
0.220
0.201
0.181
0.181
0.153
0.105
0.065
-0.020
-0.027
-0.083
-0.162
-0.329
-0.868

Std.
Error
0.158
0.084
0.109
0.066
0.037
0.046
0.037
0.047
0.081
0.040
0.081
0.039
0.058
0.027
0.033
0.035
0.028
0.007
0.002
0.039
0.057
0.069
0.178

47

pValue
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.005
0.000
0.007
0.000
0.002
0.000
0.000
0.003
0.020
0.002
0.000
0.033
0.005
0.000
0.000

Odds
Ratio
0.006
89.250
1.709
1.627
1.541
1.498
1.378
1.264
1.256
1.249
1.246
1.223
1.199
1.198
1.165
1.111
1.068
0.980
0.974
0.920
0.851
0.720
0.420

95% CI
lower
0.005
76.034
1.376
1.432
1.434
1.368
1.282
1.152
1.068
1.156
1.061
1.133
1.069
1.137
1.092
1.037
1.010
0.968
0.970
0.853
0.761
0.628
0.292

95% CI
upper
0.009
105.650
2.112
1.854
1.656
1.639
1.481
1.386
1.469
1.350
1.459
1.318
1.341
1.263
1.243
1.190
1.128
0.993
0.977
0.994
0.953
0.822
0.586

Chapter 3
Bleeding Risk Factors and Time-to-Event Analysis of Older Veterans
Prescribed Warfarin or Direct Oral Anticoagulants

3.1

Background
The oral anticoagulant (OAC) warfarin has been used for more than 60 years to help

reduce the risk of blood clot formation associated with conditions such as atrial fibrillation and
following acute myocardial infarction, but is associated with an increased risk of bleeding.15
Previous studies have found that use of warfarin doubled the risk of bleeding over those not
prescribed an OAC.15 Studies have also found that 3 – 12% of patients prescribed warfarin
experienced a major bleeding event,17,55 and 2% died following major bleeding.17 A study
published in 2008 found that in the United States gastrointestinal bleeding accounted for
approximately 300,000 hospital admissions per year, with an average length of stay of 6.53 days,
and total costs of $2.5 billion annually.95
New or Direct OACs (DOACs), were first approved by the FDA in 2010,26 and while
there are several studies comparing the risk of bleeding between DOACs and
warfarin,14,27,29,34,86,96–98 there are few studies comparing the risk factors for bleeding between
DOACs and warfarin among veterans. Identifying risk factors could prevent the morbidity,
mortality, and cost resulting from bleeding following OAC prescription among veterans.
The objectives of this study were to identify risk factors for gastrointestinal and
intracranial bleeding and to calculate the relative risk of bleeding over time through time-toevent analysis among veterans age 50 to 89 who were prescribed warfarin or DOACs using a
retrospective cohort design. In undertaking time-to-event analysis, this study sought to replicate
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previous research by Hippisley-Cox34 in this cohort of older veterans. This study was approved
by the U.S. Department of Veterans Affairs (VA), Veterans Integrated Service Network- (VISN) 2 Institutional Review Board, Research and Development Committee, and Safety Committee.
3.2

Data and Methods

3.2.a Participants and Data Source
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code and
at least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30,
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based
Outpatient Clinic in Pennsylvania.62 The first OAC prescription on or after October 1, 2010 was
used as the index date. Time-to-event for bleeding was calculated from the index date to the date
of the first ICD-9 or ICD-10 code for gastrointestinal or intracranial bleeding (see Appendix 1
for list) in the subject’s electronic health record. The cohort was followed until September 30,
2015. The study period was October 1, 2010 through September 30, 2015, for a total of five
Federal fiscal years – the common reporting cycle for VA. The 5,010 subjects contributed 10,754
person-years of observation time to the study. Ninety-three percent (n=4,670) of subjects were
followed until the end of the study. Due to their small numbers, gastrointestinal and intracranial
bleeding events were grouped together for regression and time-to-event analyses.
3.2.b Study Variables
The primary dependent variable was the presence of an ICD-9 or ICD-10 Code for
gastrointestinal or intracranial bleeding (see Appendix 1), recorded in the dataset as a
dichotomous variable. Independent variables included a categorical variable for OAC
prescription (warfarin or DOAC: rivaroxaban, dabigatran, or apixaban). Exposure to an OAC
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was determined by classifying subjects as having a prescription for an OAC at the time of a
bleeding event only if the prescription preceded the bleeding event by five or more days,
resulting in a 5-day blackout period. Subjects included in the cohort did not have a prescription
for an OAC in the six months prior to their index date.
Other dichotomous independent variables were: prescriptions for medications associated
with bleeding34 (aspirin, non-aspirin antiplatelet medications, non-steroidal anti-inflammatory
drugs (NSAIDS), statins, antidepressants, amiodarone, and antifungals), diagnosis of
hypertension, chronic kidney disease, liver disease, history of stroke or bleeding (see Appendix
2), congestive heart failure, diabetes, atrial fibrillation, deep vein thrombosis, cancer, pulmonary
embolism, non-bleeding peptic ulcer, acute myocardial infarction, alcohol abuse, and heart valve
replacement. Other dichotomous variables were low platelet count at index and a diagnosis or
procedure code for heart valve replacement. Demographic variables included age and number of
prescriptions at index date as continuous variables, and male gender, obese (BMI > 30), married,
smoker, and white non-Hispanic race/ethnicity as dichotomous variables. Several variables were
included as proxy measures for socioeconomic status, including insurance coverage, exemption
from VA copayment (an indicator of low income), and having a service-connected disability
rating (a documented chronic physical or mental disability attributed to an individual’s military
service – as an indicator of inability to work) as dichotomous variables. Median household
income, Townsend score, and percent rural (for county of residence) were included as
continuous variables. Zip code-level data was obtained through the U.S. Census Bureau
American Community Survey website,67 and county-level data was obtained from the National
Center for Health Statistics.65
3.2.c

Townsend Score
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The Townsend score is a population measure that estimates material deprivation,68 and
has been used in the U.K. for many years to estimate relative deprivation and measure
correlations between deprivation and health status.34,69 The Townsend score is an unweighted
sum of four area-level measures: percent of households with no vehicle, more than one occupant
per room (overcrowding), dwellings which are renter-occupied, and unemployment.69 The
Townsend score has been shown to correlate well with health-related measures such as overall
health, depression, and long-term illness.69 A 2015 study found that median household income
approximated deprivation as well as the Townsend score did,70 though studies from both the
U.K. and U.S. have found that the Townsend score may not accurately reflect relative
deprivation in urban areas.69–72
3.2.d Analysis Approach
Analyses were completed using R version 3.2.0. Kaplan-Meier and survival (time-toevent) curves were generated for the entire cohort, for the subset of subjects with a diagnosis of
atrial fibrillation, and the subset of subjects age 75 or older. Subgroup analysis for subjects with
a diagnosis of atrial fibrillation was conducted because several previous studies included only
subjects with a diagnosis of atrial fibrillation, so this subgroup analysis would allow for direct
comparison with those studies.14,86,89 Subgroup analysis for subjects age 75 or older was
conducted because a recent non-veteran population-based study found risk of bleeding higher
among subjects age 75 or older prescribed DOACs compared to those prescribed warfarin.27 This
subgroup analysis was intended to confirm or refute this finding in this cohort of older veterans.
Time-to-event estimates were calculated at < 1, 1-12, 24, 36, 48, and 60 months of study
for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or older. Chisquare tests were used to calculate statistical significance in time-to-event for bleeding between
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those with a prescription for warfarin and DOACs. Cox Proportional Hazards regression models
were developed to identify independent risk factors associated with gastrointestinal or
intracranial bleeding using the following formula:99
h(t) = h0(t) X exp(b1x1 + b2x2 + …bnxn)
Where h(t), the hazard function, is a product of the baseline hazard, h0(t), and the exponentiation
of a sum of coefficients, each of which is a measure of the impact that coefficient had on the
hazard function.99
Final models for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects
age 75 or older were reached by using an iterative process where groups of variables were added
to the baseline hazard (survival object) and OAC category outcome, starting with demographic
variables (age, male gender, married, white non-Hispanic race, smoker, and obese), then adding
medications (aspirin, antiplatelet medications, NSAIDS, steroids, statins, antidepressants,
amiodarone, antifungals, and the number of prescription medications as index), diagnoses
(diabetes, congestive heart failure, hypertension, atrial fibrillation, chronic kidney disease, liver
disease, history of stroke, pulmonary embolism, deep vein thrombosis, cancer, ulcer, acute
myocardial infarction, history of bleeding, low platelet count at index, and heart valve
replacement), and socioeconomic variables (disability, insurance coverage, exempt from VA
copayment, median household income, Townsend score, and percent rural) for a full model.
Each variable not significant at a p < 0.05 level in the results was removed from the model, until
a final model was realized with all variables being statistically significant at the p < 0.05 level.
3.3

Results
The cohort consisted of 5,010 subjects. Ninety-eight percent (n=4,907) of the cohort was

male, 55% (n=2,746) were married, 90% (n=4,525) had some form of insurance coverage, and
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79% (n=3,948) were White Non-Hispanic. Ninety-three percent (n=4,672) did not experience a
bleeding event during the study period; 6% (n=298) had a diagnosis of gastrointestinal bleeding,
and less than 1% (n=40) had a diagnosis of intracranial bleeding. Two subjects died during the
study period. Eighty percent (n=3,970) of the cohort had an incident prescription for warfarin
during the study period while 20% (n=1,040) had an incident prescription for a DOAC
(dabigatran, rivaroxaban, or apixaban). Nineteen percent (n=970) had a new or renewed
prescription for aspirin, 12% (n=622) for a non-aspirin antiplatelet agent, and 33% (n=1,635) for
NSAIDS. Eighteen percent of the cohort (n=879) were current smokers. Chronic conditions were
common: 93% (n=4,634) had a diagnosis of hypertension, 52% (n=2,581) had a diagnosis of
diabetes, 31% (n=1,553) had a diagnosis of congestive heart failure, 35% (n=1,770) had a
diagnosis of cancer, 69% (n=3,438) had a diagnosis of atrial fibrillation, and 51% (n=2,556) had
a diagnosis indicating prior bleeding. Subjects prescribed DOACs were older, whiter, had a
higher median household income by Zip code, had a higher proportion who were married and
had insurance, and a lower proportion with a disability or obesity compared to subjects
prescribed warfarin. Table 3.1 further describes the cohort.
Figure 3.1 shows Kaplan-Meier and survival (time-to-event) function curves for all
subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or older. Tables 3.2,
3.3, and 3.4 show time-to-event estimates at different points in the study for all subjects, subjects
with a diagnosis of atrial fibrillation, and subjects age 75 or older by OAC category. The term
survival in the context of Kaplan-Meier, the survival function, survival estimates, and chi-square
test results refers to the absence of a bleeding event and not mortality.
Only subjects prescribed warfarin experienced bleeding events in the first 30 days
following OAC prescription; this was true for all subjects, subjects with a diagnosis of atrial

53

fibrillation, and subjects age 75 or older. Time-to-event estimates for bleeding among all subjects
prescribed DOACs and warfarin were similar for the first eight months following prescription,
with subjects prescribed DOACs having slightly more time before a bleeding event than those
prescribed warfarin (0.2 – 0.5% higher). At nine months of study this gap grew slightly, and by
the end of the study period subjects prescribed DOACs had time-to-event estimates 2.7% higher
than subjects prescribed warfarin. Among subjects with a diagnosis of atrial fibrillation, those
prescribed DOACs had slightly better time-to-event estimates starting at 1 month, and continued
to have estimates 0.6 – 1.3% higher, and 3.4% higher at the end of the study period. Among
subjects age 75 or older, those prescribed DOACs had slightly better time-to-event estimates for
the first six months of the study and at 24 and 48 months, ranging from 0.2 – 1.1% higher. For
months 7 – 12 and 36 months, this difference was reversed, and subjects prescribed warfarin had
slightly better time-to-event estimates than those prescribed DOACs, with a 1.3% difference at
month 36. These observed differences were small, and Chi square tests to compare time-to-event
estimates for bleeding between subjects prescribed DOACs and warfarin were not statistically
significant when calculated for all subjects (Chisq = 0.9, p = 0.354), for subjects with a diagnosis
of atrial fibrillation (Chisq = 2, p = 0.154), or for subjects age 75 or older (Chisq = 0, p = 0.938).
Tables 3.5, 3.6, and 3.7 show the final Cox Proportional Hazards regression model risk
factors for all subjects, subjects with a diagnosis of atrial fibrillation, and subjects age 75 or
older. A prescription for warfarin was protective against gastrointestinal or intracranial bleeding
in the all subjects final model (HR = 0.341, 95% CI 0.264, 0.440, p = 0.000), but was not a
statistically significant risk factor in the final models for subjects with a diagnosis of atrial
fibrillation (HR = 0.881, 95% CI 0.591, 1.314, p = 0.535) or subjects age 75 or older (HR =
0.654, 95% CI 0.389, 1.099, p = 0.109).
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3.4

Discussion
This study produced four main findings. First, gastrointestinal and intracranial bleeding

was not common in this cohort of older veterans prescribed OACs (6.79%). Second, only
subjects prescribed warfarin experienced bleeding in the first 30 days after prescription. This
finding is consistent with previous studies that found the highest risk of bleeding was in the first
30 days after warfarin prescription.19,20 Third, subjects age 75 and older prescribed DOACs
experienced slightly more bleeding than subjects prescribed warfarin at 7 – 12 and 36 months
after prescription. Even though this finding was not statistically significant, it is suggestive and
consistent with prior research.27 The average age of subjects in this study prescribed DOACs was
75.54, while the average age of subjects prescribed warfarin was 71.76.
Fourth, this study found that risk factors for gastrointestinal and intracranial bleeding
varied between all subjects and the subgroups analyzed. This study found that prescriptions for
antidepressants (HR = 1.35, 95% CI 1.07, 1.70, p=0.012) or statins (HR = 1.31, 95% CI 1.05,
1.63, p=0.018) were the strongest risk factors for gastrointestinal or intracranial bleeding for all
subjects, while being married was protective (HR = 0.007, 95% CI 0.003, 0.016, p=0.00). A
prescription for warfarin was also protective (HR = 0.341, 05% CI 0.26, 0.44, p=0.00), and it is
unclear why this would be the case, especially considering subgroup analyses on subjects with a
diagnosis of atrial fibrillation and subjects age 75 or older, which found that a prescription for
warfarin was not a statistically significant risk factor. Although it should be noted that a 5-day
blackout period was used to determine OAC exposure, so that could have had an impact on
results.
Subgroup analyses identified history of bleeding as the strongest risk factor for subjects
with a diagnosis of atrial fibrillation (HR = 37.89, 95% CI 15.56, 92.25, p=0.00) and subjects age
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75 or older (HR = 21.15, 95% CI 7.93, 56.45, p=0.00). Findings in this study related to risk
factors are consistent with previous research, but race/ethnicity, smoking status, BMI, lab values,
other medication classes, and socioeconomic variables (Townsend score, median household
income, percent service-connected disability, and insurance coverage) were not significant,
which is not consistent with previous studies.14,27,29,34,86,96–98
It is difficult to interpret the results of this study, because few prior studies focus on
veterans, and the majority of studies on the general population tend to focus on subjects with a
single diagnosis as an indication for OAC prescription – usually atrial fibrillation or venous
thromboembolism. Compared to the general population veterans tend to be older, have a higher
proportion of males, and more chronic diseases.8 Not all eligible veterans seek healthcare
through the VA system, and those who do may also receive care elsewhere, though VA patients
in general are less likely to have health insurance.8 It is possible that differences in veterans as a
population can account for the differences in the results of this study, but why that would be the
case is a subject for further research.
With the availability of more options for oral anticoagulants, patients and providers need
to have information that allows them to weigh the benefits and risks associated with each.
Because the first studies comparing warfarin with DOACs relied on clinical trials data, it was
difficult to translate those findings to patients seen in usual practice, as many clinical trials
excluded subjects with risk factors for bleeding.96 Three times as many veterans in this study
were prescribed warfarin (n=3,970) as DOACs (n=1,040). It is important to understand how
veterans as a population might benefit from increasing the number prescribed DOACs as the
large number of Vietnam veterans age and have an increased risk of atrial fibrillation and other
chronic conditions where treatment with an OAC could be indicated, however caution may be
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warranted when those in need of anticoagulation are age 75 or older or have a history of
bleeding.
3.5

Limitations
This study had several limitations. Most of the data used in this study came from a

clinical and administrative database, and did not include private insurance claims or non-VA
pharmacy benefit data, so services and prescriptions obtained outside the VA healthcare system
were not included, although every effort was made to include those veterans who appeared to
receive care at the VA as their primary site of care. The subjects included in this study were from
New York and New Jersey, and regional differences in demographics may limit the
generalizability of the findings in this study to the rest of the United States. This study did not
compare time-to-event for bleeding between warfarin and each DOAC (dabigatran, rivaroxaban,
and apixaban) separately. The relatively low numbers of DOAC prescriptions, and the very low
number of outcomes prevented such analyses in this cohort. Also, this study included subjects
with a variety of diagnoses that are common indications for OAC prescription. In future research
it may be important to include comparisons of each DOAC with warfarin, and analyze
subpopulations with specific diagnoses, because some recent studies have found differences in
outcomes in both of these areas,96,98 though these studies did not focus on veterans.
3.6

Conclusion
This study compared time-to-event for gastrointestinal and intracranial bleeding for

veterans prescribed warfarin and DOACs over a five-year period, and identified independent risk
factors for bleeding. Differences in time-to-event estimates between subjects prescribed warfarin
and DOACs were small and not statistically significant. The risk factors with the strongest
association with gastrointestinal or intracranial bleeding was a concurrent prescription for
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antidepressants for all subjects, and a history of bleeding for subjects with a diagnosis of atrial
fibrillation and age 75 or older.

58

Figure 3.1. Kaplan-Meier and Survival (time-to-event) Function Curves for All Subjects (a, b),
Subjects with a Diagnosis of Atrial Fibrillation (c, d), and Subjects Age 75 or Older (e, f), by
OAC Category. For the purposes of this figure, the term survival refers to the period of time a
subjects did not experience a bleeding event.
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Table 3.1. Baseline Cohort Characteristics by OAC Prescription Category.
Variable
Number of Subjects
Age (mean (sd))
Age >= 75 (%)
Male (%)
Married (%)
White Non-Hispanic Race (%)
Smoker (%)
Obese (BMI > 30) (%)
Disability (%)
Insurance Coverage (%)
Exempt from VA Copayment (%)
Median Household Income (mean (sd))
Townsend score (mean (sd))
Percent Rural (mean (sd))
Time-to-event (days) (mean (sd))
Months of Observation (mean (sd))
Censor Type (%)
Death
End of Study
Gastrointestinal Bleeding
Intracranial Bleeding
Bleeding Event (Outcome) (%)
Aspirin (%)
Non-aspirin Antiplatelet Medication (%)
NSAIDS (%)
Steroids (%)
Statins (%)
Antidepressants (%)
Amiodarone (%)
Antifungal Medication (%)
Number of Prescriptions (mean (sd))
Diabetes (%)
Congestive Heart Failure (%)
Hypertension (%)
Atrial Fibrillation (%)
Chronic Kidney Disease (%)
Liver Disease (%)
History of Stroke (%)
Pulmonary Embolism (%)

DOAC

Warfarin

1,040
75.54 (8.62)
552 (53.1)
1,024 (98.5)
649 (62.4)
857 (82.4)
131 (12.6)
130 (12.5)
401 (38.6)
980 (94.2)
112 (10.8)
69,941.75 (26,385.63)
0.56 (0.43)
15.07 (22.50)
381.12 (346.41)
12.72 (11.55)

3,970
71.76 (8.97)
1,395 (35.1)
3,883 (97.8)
2,097 (52.8)
3,091 (77.9)
748 (18.8)
789 (19.9)
1,699 (42.8)
3,545 (89.3)
313 (7.9)
60,797.70 (23,632.76)
0.56 (0.42)
21.21 (25.30)
874.75 (527.96)
29.17 (17.61)

0 (0.0)
1,004 (96.5)
31 (3.0)
5 (0.5)
36 (3.5)
126 (12.1)
123 (11.8)
254 (24.4)
330 (31.7)
554 (53.3)
224 (21.5)
74 (7.1)
263 (25.3)
3.92 (2.26)
498 (47.9)
265 (25.5)
973 (93.6)
891 (85.7)
170 (16.3)
115 (11.1)
157 (15.1)
81 (7.8)

2 ( 0.1)
3,666 (92.3)
267 (6.7)
35 (0.9)
302 (7.6)
844 (21.3)
499 (12.6)
1,381 (34.8)
1,890 (47.6)
2,257 (56.9)
1,111 (28.0)
346 (8.7)
1,378 (34.7)
3.91 (2.75)
2,083 (52.5)
1,288 (32.4)
3,661 (92.2)
2,547 (64.2)
887 (22.3)
590 (14.9)
732 (18.4)
594 (15.0)
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p-Value
<0.001
<0.001
0.231
<0.001
0.002
<0.001
<0.001
0.015
<0.001
0.004
<0.001
0.859
<0.001
<0.001
<0.001
<0.001

<0.001
<0.001
0.553
<0.001
<0.001
0.042
<0.001
0.111
<0.001
0.888
0.009
<0.001
0.163
<0.001
<0.001
0.002
0.014
<0.001

Deep Vein Thrombosis (%)
Cancer (%)
Ulcer (%)
Acute Myocardial Infarction (%)
Alcohol Abuse (%)
History of Bleeding (%)
Low Platelet Count (< 150,000/mcl) (%)
Heart Valve Replacement (%)

146 (14.0)
353 (33.9)
52 (5.0)
60 (5.8)
459 (44.1)
459 (44.1)
37 (3.6)
29 (2.8)

1,194 (30.1)
1,417 (35.7)
229 (5.8)
333 (8.4)
2,097 (52.8)
2,097 (52.8)
88 (2.2)
262 (6.6)

<0.001
0.31
0.377
0.006
<0.001
<0.001
0.018
<0.001

Table 3.2. Time-to-Event Estimates for All Subjects.
DOAC
Month At Risk # Events #
<1
1,040
0
1
1,017
8
2
951
2
3
891
2
4
832
3
5
771
3
6
701
2
7
647
1
8
597
2
9
552
1
10
519
1
11
484
1
12
439
1
24
168
6
36
77
3
48
13
0
60
0
0

Warfarin

Time-to-Event
(No Bleeding Event) At Risk # Events #
100.00%
3,970
10
99.20%
3,937
30
99.00%
3,860
15
98.80%
3,791
11
98.40%
3,709
10
98.00%
3,645
19
97.80%
3,560
7
97.60%
3,479
10
97.30%
3,408
9
97.10%
3,331
10
96.90%
3,269
10
96.70%
3,195
8
96.50%
3,128
8
94.50%
2,336
59
91.80%
1,539
45
91.80%
829
31
NA
70
10

Time-to-Event
(No Bleeding Event)
99.70%
99.00%
98.60%
98.30%
98.10%
97.50%
97.30%
97.10%
96.80%
96.50%
96.20%
96.00%
95.70%
93.70%
91.50%
89.10%
87.40%

Table 3.3. Time-to-Event Estimates for Subjects with a Diagnosis of Atrial Fibrillation.
DOAC
Month
At Risk # Events #
<1
891
0
1
875
4
2
825
2
3
770
1

Warfarin

Time-to-Event
(No Bleeding Event) At Risk # Events #
100.00%
2,547
8
99.50%
2,525
20
99.30%
2,472
11
99.20%
2,426
7
61

Time-to-Event
(No Bleeding Event)
99.70%
98.90%
98.50%
98.20%

4
5
6
7
8
9
10
11
12
24
36
48
60

718
666
604
560
516
476
447
420
385
156
71
11
0

3
2
2
0
2
1
1
1
1
6
3
0
0

98.80%
98.50%
98.10%
98.10%
97.80%
97.50%
97.30%
97.10%
96.80%
94.60%
91.70%
91.70%
NA

2,374
2,331
2,269
2,213
2,166
2,107
2,068
2,017
1,975
1,456
969
519
40

6
13
2
7
6
9
5
2
6
42
32
21
8

97.90%
97.40%
97.30%
97.00%
96.70%
96.30%
96.10%
96.00%
95.70%
93.30%
90.80%
88.30%
86.40%

Table 3.4. Time-to-Event Estimates for Subjects Age 75 or Older.
DOAC
Month
At Risk # Events #
<1
552
0
1
544
2
2
510
2
3
475
2
4
441
1
5
408
3
6
367
1
7
342
1
8
318
1
9
297
1
10
279
0
11
263
1
12
238
0
24
102
1
36
47
3
48
6
0
60
0
0

Warfarin

Time-to-Event
(No Bleeding Event) At Risk # Events #
100.00%
1,395
3
99.60%
1,383
10
99.20%
1,351
4
98.80%
1,330
6
98.60%
1,308
3
97.90%
1,292
5
97.60%
1,261
1
97.30%
1,225
1
97.00%
1,196
3
96.70%
1,164
1
96.70%
1,148
3
96.30%
1,119
2
96.30%
1,101
3
95.80%
814
18
91.40%
545
14
91.40%
279
9
NA
21
2

Time-to-Event
(No Bleeding Event)
99.80%
99.10%
98.80%
98.30%
98.10%
97.70%
97.60%
97.60%
97.30%
97.20%
97.00%
96.80%
96.50%
94.70%
92.70%
90.50%
89.60%

Table 3.5. Cox Proportional Hazards Regression Final Model – All Subjects.
Variable
Warfarin (DOAC was comparator)
Married

Hazard Ratio Lower 95% CI Upper 95% CI p-Value
0.341
0.264
0.440
0.000
0.007
0.003
0.016
0.000
62

Statins
Antidepressants
Antifungals

1.307
1.348
0.757

1.048
1.068
0.597

1.630
1.701
0.961

0.018
0.012
0.022

Table 3.6. Cox Proportional Hazards Regression Final Model – Subjects with a Diagnosis of
Atrial Fibrillation.
Variable
Warfarin (DOAC was comparator)
Age
Aspirin
Congestive Heart Failure
Chronic Kidney Disease
Stroke
Ulcer
Acute Myocardial Infarction
History of Bleeding

Hazard Ratio Lower 95% CI Upper 95% CI p-Value
0.881
0.591
1.314
0.535
0.976
0.960
0.991
0.002
1.650
1.237
2.201
0.001
1.349
1.039
1.753
0.025
1.352
1.031
1.774
0.030
1.490
1.122
1.979
0.006
2.080
1.408
3.073
0.000
1.854
1.341
2.565
0.000
37.888
15.562
92.246
0.000

Table 3.7. Cox Proportional Hazards Regression Final Model – Subjects Age 75 or Older.
Variable
Warfarin (DOAC was comparator)
Male Gender
Aspirin
Steroids
Antidepressants
Ulcer
History of Bleeding

Hazard Ratio Lower 95% CI Upper 95% CI p-Value
0.654
0.389
1.099
0.109
0.337
0.115
0.993
0.049
1.674
1.036
2.705
0.036
1.549
1.036
2.314
0.033
1.634
1.046
2.553
0.031
1.841
1.001
3.384
0.050
21.152
7.926
56.448
0.000
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Chapter 4
Predicting Bleeding Risk in Older Veterans Prescribed Warfarin or Direct Oral
Anticoagulants Using Traditional and Machine Learning Methods

4.1

Background
Oral anticoagulants (OACs) are effective in reducing the risk of blood clot formation, a

complication associated with stroke and deep vein thrombosis, but OACs are associated with an
increased risk of bleeding.15,100 Several clinical algorithms have been developed to help predict
who among those prescribed OACs is at highest risk of bleeding.20,24,33,34,100 These algorithms
were developed so providers could assess a handful of risk factors during a patient visit, and
using the algorithm name as a mnemonic device (HAS-BLED, ORBIT, ATRIA), calculate a risk
score for the patient. While it is possible to use computer programs to automate calculation of
these scores and generate scores for patient populations, this has not been a regular practice of
healthcare organizations. Reducing harm to patients taking anticoagulants has been a Joint
Commission Patient Safety Goal (PSG) for hospitals, ambulatory care, and long-term care since
2008.36 Performance elements associated with this goal include baseline INR testing, following
evidence-based guidelines, and having and following written facility policies and guidelines
related to anticoagulant management.37 A randomized controlled trial from Canada published
five years prior to the PSG found patients taking OACs managed by anticoagulation clinics had
an INR Therapeutic Time in Range (TTIR) of 82% versus 76% for those patients managed by
family medicine doctors.38 Despite these and similar findings in other studies, many patients
taking anticoagulants are not managed in specialized clinics.39
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In July 2015 the Veteran’s Health Administration (VHA) published a new policy on
anticoagulation therapy management.40 This policy requires providers with patients on
anticoagulant therapy to perform periodic risk assessments of these patients, including assessing
bleeding risk and calculating TTIR.40 Although efforts are underway to enable calculation of
TTIR across the VHA for patients prescribed OACs, a method or model for predicting bleeding
risk has yet to be developed. This study will help VHA facilities comply with this policy, and
also help non-VHA facilities comply with similar local policies and The Joint Commission
Patient Safety Goal.
The objectives of this study were to develop and compare models to predict
gastrointestinal and intracranial bleeding among veterans age 50 to 89 who were prescribed
warfarin or Direct OACs (DOACs) using a retrospective cohort design. This study was approved
by the U.S. Department of Veterans Affairs (VA), Veterans Integrated Service Network- (VISN) 2 Institutional Review Board, Research and Development Committee, and Safety Committee.
4.2

Data and Methods

4.2.a Participants and Data Source
Subjects included in the study were veterans age 50 to 89 with a five-digit Zip code and
at least two primary care visits at a VISN-2 facility between October 1, 2010 and September 30,
2011, and assigned a primary care provider. The VISN-2 network includes 14 hospitals and 57
Community Based Outpatient Clinics in New York and New Jersey, and one Community Based
Outpatient Clinic in Pennsylvania.62 The first OAC prescription on or after October 1, 2010 was
used as the index date. Subjects were considered to have had a bleeding event if an ICD-9 or
ICD-10 code for bleeding (see Appendix 1 for list) was present in the subject’s electronic health
record after the index date. Exposure to an OAC was determined by classifying subjects as
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having a prescription for an OAC at the time of a bleeding event only if the prescription
preceded the bleeding event by five or more days, resulting in a 5-day blackout period. Only
subjects who did not have a prescription for any OAC for at least 180 days prior to their index
date were included in the cohort. The cohort was comprised of 5,010 subjects and was followed
until September 30, 2015. The study period was October 1, 2010 through September 30, 2015,
for a total of five Federal fiscal years – the common reporting cycle for VA. The 5,010 subjects
contributed 10,754 person-years of observation time to the study. Ninety-three percent (n=4,670)
of subjects were followed until the end of the study. Due to their small numbers, gastrointestinal
and intracranial bleeding events were grouped together for analyses.
Clinical and administrative data were obtained by querying the VA corporate data
warehouse, the repository for VA electronic health record data. Each subject’s Zip code of
residence was matched to U.S. Census Bureau American Community Survey (ACS) data, which
allowed for the inclusion of several Zip code-level variables (described below). In addition, each
subject’s county of residence was matched to the National Center for Health Statistics (NCHS)
Urban-Rural Classification Scheme for Counties, which allowed the inclusion of a variable to
examine the relationship between urbanization and risk of bleeding.65
4.2.b Study Variables
In order to accommodate multiple methods and models run from the same dataset, all
variables were coded as binary (1 or 0). The primary dependent variable was the presence of an
ICD-9 or ICD-10 Code for gastrointestinal or intracranial bleeding (see Appendix 1). The
primary independent variable was a prescription for warfarin (versus a DOAC – dabigatran,
rivaroxaban, or apixaban). Other binary explanatory variables included married; serviceconnected disability (any disability rating from the VA); prescription for aspirin, non-aspirin
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antiplatelet medications, nonsteroidal anti-inflammatory drugs (NSAIDS), steroids, statins,
antidepressants, carbamazepine, phenytoin, or antifungals; white non-Hispanic race; current
smoker; diagnosis of diabetes, congestive heart failure, hypertension, atrial fibrillation, chronic
kidney disease, liver disease, chronic pancreatitis, stroke, deep vein thrombosis, cancer,
esophageal varices, a history of bleeding (see Appendix 2), alcohol abuse; obese (body mass
index >= 30); low platelet count (< 150,000/mcl); and male gender. Continuous variables
included age, percent rural by county (according to NCHS),65 months of observation time
contributed to the study, count of total outpatient prescriptions at index, Townsend score, and
median household income by Zip code. Zip code-level data (median household income and
components of the Townsend score) were obtained from the U.S. Census Bureau American
Community Survey website.67 Townsend score, a measure of socioeconomic deprivation, is
described in detail elsewhere.34,68
4.2.c

Analysis Approach
Analyses were completed using R version 3.4.1. The dataset was randomly split in half,

resulting in 2,505 subjects in the training dataset, and 2,505 subjects in the validation dataset. Six
techniques were used to build models to predict gastrointestinal or intracranial bleeding: (1)
ATRIA,20 ORBIT,33 and HAS-BLED24 scores were calculated then added to the analysis dataset
as continuous numeric variables. Logistic regression was used to calculate the risk of bleeding
using these three traditional algorithms, with the corresponding score as the single predictor in
each model. Logistic regression using an algorithm to choose subsets of the strongest predictors
from all available variables was employed to choose models with the best 1, 3, 5, and 10
variables. (2) Time-to-event analysis was used to evaluate the QBLEED algorithm and included
only those variables used in the published validation study.34 Machine learning algorithms
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employed included: (3) Least absolute shrinkage and selection operator (lasso) and (4) elastic net
– two penalized logistic regression variants, and (5) Adaboost and (6) Classification and
Regression Trees (CART) – two decision tree-based algorithms. Models were trained using the
training dataset and then evaluated using the validation dataset.
4.2.d Method for Evaluating Predictive Models
Models run against the validation dataset were evaluated according to five unweighted
measures, using criteria from previous research and texts: (1) classification error, (2) calibration,
(3) sensitivity, (4) positive predictive value, and (5) area under the receiver operating curve .31,47
Table 4.1 shows the measures, definitions, and evaluation criteria. A score for each model was
constructed using the following scheme: the best performing model for each measure was
awarded three points, the second best model two points, and the third best model one point.
Points for each measure were added together for a total model score. Evaluation measures for all
models will be shown, and then the two best models will be discussed in more detail.
Gains tables were produced for the two best models to evaluate how well they were able
to correctly classify subjects,47 and to aid decision making in terms of whether or not an
intervention based on one of the models would be feasible and likely to have the desired impact.
For example, in the context of the current study, if the VA wanted to develop an intervention
targeting veterans who were prescribed OACs and identified as being at high risk for subsequent
bleeding, it would be valuable to know at what risk level the intervention should be triggered, as
well as the anticipated number of veterans who would likely meet this risk threshold, and how
many veterans could be expected to actually have a bleeding event at the set threshold level.
Gains show how the predictions made by the model are better than chance (i.e. what is gained by
using the model), and are evaluated using the measures accuracy, sensitivity, and positive
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predictive value (PPV).47,101 Accuracy is defined as 1 – error rate, while PPV is defined as the
proportion of events predicted by the model that are correct, and sensitivity is defined as the
proportion of true events predicted by the model.101 Gains tables for the ORBIT and logistic
regression with subset of 5 best variables models are shown in Tables A.3.1 and A.3.2 of
Appendix 3.
Predicted probabilities were plotted for the two best models to visually depict how
subjects were grouped according to predicted risk. Lift charts were generated to visually
illustrate the gain derived from the model. The Area Under the Curve (AUC) is a statistical
measure used to assess how well a model predicts whether subjects will experience a specified
outcome.30
4.3

Results
The cohort was comprised of 5,010 subjects. Ninety-eight percent (n=4,907) of the cohort

was male, 55% (n=2,746) were married, and 79% (n=3,948) were White Non-Hispanic race.
Ninety-three percent (n=4,672) did not experience a bleeding event during the study period; 6%
(n=298) had a diagnosis of gastrointestinal bleeding, and less than 1% (n=40) had a diagnosis of
intracranial bleeding. Eighty percent (n=3,970) of the cohort had an incident prescription for
warfarin during the study period while 20% (n=1,040) had an incident prescription for a DOAC.
Nineteen percent (n=970) had a new or renewed prescription for aspirin, 12% (n=622) for a nonaspirin antiplatelet medication, and 33% (n=1,635) for NSAIDS. Thirty-eight percent (n=1,902)
of the cohort had never smoked, 44% (n=2,229) were former smokers, and 18% (n=879) were
current smokers. Chronic conditions were common: 93% (n=4,634) had a diagnosis of
hypertension, 52% (n=2,581) had a diagnosis of diabetes, 31% (n=1,553) had a diagnosis of
congestive heart failure, 35% (n=1,770) had a diagnosis of cancer, 69% (n=3,438) had a
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diagnosis of atrial fibrillation, and 51% (n=2,556) had a diagnosis indicating prior bleeding.
Table 4.2 further describes the cohort.
Model performance varied greatly. No single model performed the best on every
evaluation measure. Two models had scores in the top three for three evaluation measures: the
ORBIT algorithm and logistic regression with 5 variable subset. Three models (logistic
regression 10 variable subset, elastic net, and Adaboost) did not have any evaluation measures in
the top three in terms of performance. Table 4.3 shows the models, variables, and results.
Overall, the ORBIT algorithm performed the best with a score of 7 with the lowest error,
highest PPV, and third highest sensitivity. Logistic regression with 5 variable subset had a score
of 5 with the second highest PPV and AUC and third lowest error. The ATRIA algorithm had a
score of 4 and tied for second lowest error and had the second best calibration. Two machine
learning algorithms had scores in the top three for two evaluation measures. The lasso algorithm
had the third best calibration and third highest AUC. The CART algorithm had the second
highest sensitivity and third highest PPV. All models had poor sensitivity. Half of the models
had excellent calibration. Two-thirds of the models had a PPV of zero; despite this seven of 12
models had an AUC between 0.80 and 0.89.
Using logistic regression the ORBIT score had an odds ratio of 2.15 (95% confidence
interval 1.88, 2.48). As shown in table 4.3, bleeding history was the single best predictor for a
bleeding event in the study population. Table 4.4 shows the odds ratios and confidence intervals
for the logistic regression model with subset of best 5 variables, and illustrates how strong the
association between bleeding history and subsequent bleeding event is compared to the other top
five predictors. Bleeding history is a component of the ORBIT score.33

70

Tables 1 and 2 of Appendix 3 show gains tables for both the ORBIT model and the
logistic regression model with subset of best 5 variables. The gains tables show that using the
ORBIT model an intervention could be developed for any patient with a risk score of 0.21 or
greater, which was approximately 10% (n=235) of the study population included in the
validation dataset. At this threshold the model would accurately predict bleeding 93% of the
time, with a sensitivity of 11% and a PPV of 46%. Using the subset of five best variables model,
a threshold of 0.30 or greater would include approximately 10% (n=259) of the study population
included in the validation dataset and accurately predict bleeding 92% of the time with a
sensitivity of 24% and a PPV of 37%. At a threshold of 0.21 the sensitivity for the ORBIT model
is lower than for the subset of five best variables at a threshold of 0.30 (11% versus 24%,
respectively), however the ORBIT model has higher PPV at 46% versus 37%, respectively.
Figure 4.1 shows predicted probability plots and lift charts for the ORBIT and the logistic
regression with subset of best five variables models. The predicted probability plots illustrate the
findings from the gains tables: that most subjects are classified as low risk. This is not entirely
surprising since the outcome is rare – only 7% of subjects experienced a bleeding event. The lift
chart for the ORBIT model shows how the model predicts bleeding events above the level of the
mean response for approximately the first 30% of subjects in the validation dataset, and then the
model does no better in predicting bleeding events than using the mean response as a predictor.
The lift chart for the logistic regression model with subset of best five variables shows that the
model predicts bleeding events better than using the mean response for approximately the first
20% of subjects in the validation dataset, and then it does no better, and in some cases does
worse than using the mean response as a predictor.
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The lasso algorithm selected the same five variables as logistic regression with the best
subset algorithm. Table 3 in Appendix 3 shows the variables selected by the lasso model and
their corresponding odds ratios. As with the logistic regression models, the lasso model found
bleeding history to be the strongest predictor.
Figure 1 in Appendix 3 shows the decision tree for the CART machine learning
algorithm. Again, bleeding history was the top predictor, followed by months of observation,
warfarin prescription, and congestive heart failure. Interestingly, the decision tree included other
variables – such as age, percent rural, median household income, marital status, and NSAIDS
prescription – that were not significant predictors in the other models.
4.4

Discussion
The main finding of this study was that a predictive model based on the ORBIT score33

performed better than several other traditional and machine learning algorithms, with an AUC of
0.75. A logistic regression model with a subset of 5 best variables algorithm performed second
best, and had an AUC of 0.85. Two machine learning algorithms also performed fairly well in
predicting bleeding risk: a lasso model with an AUC of 0.85, and a CART model with an AUC
of 0.82. Overall model performance was based on five different performance measures; many
studies evaluated predictive model performance using only AUC. No single model scored best in
the five measures used to evaluate them. Even in the case of the two best models the
performance based on the set of five measures chosen was not strong. Models could have been
evaluated differently by weighting the measures or choosing different measures.
Atrial fibrillation patients are commonly prescribed OACs, making them a well-studied
patient population, and the source for the traditional bleeding risk algorithms used as
comparators for this study. Although developed using atrial fibrillation patients, these algorithms
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have been used to predict bleeding risk among patients other than those diagnosed with atrial
fibrillation. The oldest of the traditional algorithms evaluated in this study was HAS-BLED.24 A
study comparing HAS-BLED to other bleeding risk prediction schemes found HAS-BLED had a
higher AUC (ranging from 0.60-0.66) than the four other algorithms to which it was compared.32
The original study describing HAS-BLED as a convenient and effective predictor of bleeding
risk found an AUC range of 0.72-0.91.24 The HAS-BLED algorithm is recommended as the
preferred method for determining bleeding risk according to the European Society of
Cardiology34 and the American College of Cardiology,35 and could be considered the “gold
standard” in terms of bleeding risk prediction algorithms. The ATRIA algorithm was originally
developed to predict stroke risk in patients with atrial fibrillation,20 but it has been used to predict
bleeding risk as well.33 A study comparing ATRIA to an older algorithm (CHADS2) found that
ATRIA had an AUC of 0.73 while the older algorithm had an AUC of 0.70.20 A recent study
comparing a new bleeding risk algorithm, ORBIT, to HAS-BLED and ATRIA, found ORBIT
had an AUC of 0.67, compared to 0.64 for HAS-BLED and 0.66 for ATRIA.33 This study used a
completely different population for validating their risk models, and found the AUCs decreased
by approximately 0.05 for each of the three models during validation.33 The QBLEED score,
based on a study done in the U.K., found Townsend score was a predictor for bleeding risk.34
QBLEED is a survival model, and incorporates many of the HAS-BLED risk factors.34 The
QBLEED validation study found an AUC of 0.77 for women and 0.75 for men, but did not
directly compare results with HAS-BLED or ATRIA.34
The ability to use published algorithms to assign risk can save healthcare organizations
many hours of work in developing their own, which many facilities may not have the capability
to do. Historically the biggest shortcoming of using HAS-BLED, ORBIT, or ATRIA was that
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those algorithms were meant to be calculated manually, one patient at a time at the point of care,
and being calculated in this way they did not give healthcare providers insight into patient
populations. Using automated tools, the ORBIT score and bleeding risk could be calculated at
the point of care, and the bleeding risk of one patient could be compared to others with similar
demographics, comorbidities, and medications. The variables included in ORBIT are readily
available in electronic health records.
This study compared HAS-BLED, ATRIA, ORBIT, and QBLEED to logistic regression
and machine learning predictive models and found a model using the ORBIT score performed
best, and with a higher AUC than that found in previously published studies. The ORBIT score
includes reduced hemoglobin, hematocrit, or history of anemia, history of bleeding, insufficient
kidney function, treatment with an antiplatelet agent, and age greater than or equal to 75.33 Since
history of bleeding was the strongest predictor of bleeding in this study population it is easy to
see how ORBIT, logistic regression with 5 best variables, lasso, and CART all performed well.
The ORBIT and logistic regression with subset of 5 best variables models are simple and easy to
interpret, and can be used to predict risk among veterans using data readily available in the
electronic health record.
4.5

Limitations
This study had several limitations. Data used in this study came from a VA clinical and

administrative database, and did not include non-VA claims or pharmacy benefit data, so
services and prescriptions obtained outside the VA healthcare system were not included,
although every effort was made to include veterans who appeared to receive care at the VA as
their primary site of care. The subjects included in this study were primarily from New York and
New Jersey, and regional differences in demographics may limit the generalizability of findings
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to the rest of the United States or other countries. This study utilized minimal preprocessing of
data prior to predictive modeling, although some feature engineering was performed in order to
make all variables binary. It is possible that the use of categorical variables might change the
outcome of different models, as might more preprocessing, or other model tuning techniques
such as cross-validation, boosting, and bagging. Due to the rare outcome, data was split 50/50 for
training and validation, in order to distribute the outcome more evenly for model learning. It is
possible that different data splits might change the results of the models. Machine learning tools
perform better with larger datasets,44 and the datasets in this study totaled 2,505 subjects each
(training and validation), which is adequate for machine learning algorithms and statistical
inference, but machine learning algorithms improve with increasing amounts of data so it is
possible the machine learning algorithms used in this study would have performed better with
larger datasets. This study focused heavily on logistic regression and machine learning variants
of logistic regression, and it is possible that other machine learning algorithms for classification,
such as support vector machine, k-nearest neighbors, or discriminant analysis would have
performed differently or better. Predictive models used in this study were evaluated according to
five unweighted measures. It is possible that models could have scored differently if weighting
of measures was applied, or if different measures were selected. The model evaluation rubric for
this study resulted in the selection of models that favored specificity (identification of true
negatives) over sensitivity (identification of true positives). While this might be appropriate for
some uses, it is not preferable from a clinical point of view, where it would be better to favor
measures and models that include more false positives, because it would be better to intervene
with more patients who turned out to be false positives than to miss them with a model that
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focused on true negatives and intervene with more false negative patients and miss some who
were true positives.
4.6

Conclusion
This study compared models to predict bleeding risk among older veterans prescribed

warfarin and DOACs. Using logistic regression the ORBIT model performed the best. Logistic
regression with a subset of best 5 variables performed second best. Lasso and CART machine
learning algorithms also performed well, although no single model performed strongly in all
measures that were evaluated. This study highlights the importance of comparing modeling
techniques, as a simpler, more easily interpretable model may perform as well as a more
sophisticated one. Accurately predicting gastrointestinal and intracranial bleeding among older
veterans prescribed OACs is possible, and identifying those at highest risk of bleeding following
OAC prescription can be done easily using a few clinical variables from the electronic health
record. Because history of bleeding is such a strong predictive factor, it may be possible to
design an intervention around that single risk factor without the use of a predictive model, and
have an impact on reducing bleeding in veterans prescribed warfarin and DOACs.
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Figure 4.1. Predicted Probability Plots and Lift Charts for the ORBIT Predictive Model and the
Logistic Regression with Subset of 5 Best Variables Predictive Model.

Table 4.1. Predictive Model Evaluation Measures, Definitions, and Criteria.
Measure
Classification Error
Calibration

Definition
Percent of incorrect predictions31,47
The mean absolute difference
between predicted probability and
observed proportion31

Sensitivity

The probability that bleeding event
is predicted correctly for subjects
who had a bleeding event47
The probability of having a bleeding
event when classified as having a
bleeding event47
The overall ability of a model to
correctly classify subjects who do
and do not experience a bleeding
event47

Positive Predictive Value

Area Under the Receiver
Operating Curve
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Evaluation Criteria
Lower is better
0 – 4% = excellent
5 – 9% = very good
10 – 14% = good
15 – 20% = fair
> 20% = poor
< 0.6 = poor
0.6 – 0.69 = fair
0.7 – 0.79 = good
0.8 – 0.89 = very good
0.9 – 1.0 = excellent

Table 4.2. Baseline Cohort Characteristics by OAC Prescription Category.
Variable
Number of Subjects
Age (mean (sd))
Married (%)
Male Gender (%)
Service-Connected Disability (%)
Percent Rural (mean (sd))
Months to Bleeding Event (mean (sd))
Aspirin (%)
Non-aspirin Antiplatelet Medication (%)
NSAIDS (%)
Steroids (%)
Statins (%)
Antidepressants (%)
Carbamazepine (%)
Phenytoin (%)
Antifungals (%)
Number of Prescriptions (mean (sd))
White Non-Hispanic Race (%)
Smoker (%)
Diabetes (%)
Congestive Heart Failure (%)
Hypertension (%)
Atrial Fibrillation (%)
Chronic Kidney Disease (%)
Liver Disease (%)
Chronic Pancreatitis (%)
Stroke (%)
Deep Vein Thrombosis (%)
Cancer (%)
Esophageal Varices (%)
Bleeding History (%)
Alcohol Abuse (%)
Obese (BMI >= 30) (%)
Low Platelets (< 150,000 mcl) (%)
Townsend Score (mean (sd))
Median Household Income
(mean (sd))
HAS-BLED Score (mean (sd))
ORBIT Score (mean (sd))

DOAC
1,040
75.54 (8.62)
649 (62.4)
1,024 (98.5)
401 (38.6)
15.07 (22.50)
12.72 (11.55)
126 (12.1)
123 (11.8)
254 (24.4)
330 (31.7)
554 (53.3)
224 (21.5)
3 ( 0.3)
1 ( 0.1)
263 (25.3)
3.92 (2.26)
857 (82.4)
131 (12.6)
498 (47.9)
265 (25.5)
973 (93.6)
891 (85.7)
170 (16.3)
115 (11.1)
4 ( 0.4)
157 (15.1)
146 (14.0)
353 (33.9)
2 ( 0.2)
459 (44.1)
459 (44.1)
130 (12.5)
37 ( 3.6)
0.56 (0.43)
69,941.75
(26,385.63)
4.14 (1.32)
1.71 (1.25)
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Warfarin
3,970
71.76 (8.97)
2,097 ( 52.8)
3,883 (97.8)
1,699 ( 42.8)
21.21 (25.30)
29.17 (17.61)
844 ( 21.3)
499 ( 12.6)
1,381 ( 34.8)
1,890 ( 47.6)
2,257 ( 56.9)
1,111 ( 28.0)
19 ( 0.5)
10 ( 0.3)
1,378 ( 34.7)
3.91 (2.75)
3,091 ( 77.9)
748 ( 18.8)
2,083 ( 52.5)
1,288 ( 32.4)
3,661 ( 92.2)
2,547 ( 64.2)
887 ( 22.3)
590 ( 14.9)
94 ( 2.4)
732 ( 18.4)
1,194 ( 30.1)
1,417 ( 35.7)
27 ( 0.7)
2,097 ( 52.8)
2,097 ( 52.8)
789 ( 19.9)
88 ( 2.2)
0.56 (0.42)
60,797.70
(23,632.76)
4.25 (1.44)
1.78 (1.34)

pValue
<0.001
<0.001
0.231
0.015
<0.001
<0.001
<0.001
0.553
<0.001
<0.001
0.042
<0.001
0.574
0.56
<0.001
0.888
0.002
<0.001
0.009
<0.001
0.163
<0.001
<0.001
0.002
<0.001
0.014
<0.001
0.31
0.106
<0.001
<0.001
<0.001
0.018
0.859
<0.001
0.033
0.173

ATRIA Score (mean (sd))
Bleeding Event (%)

6.18 (2.20)
36 ( 3.5)

5.81 (2.60)
302 ( 7.6)

<0.001
<0.001

Table 4.3. Models and Results.
Model
(Variables (n))
Logistic
Regression (1)
Logistic
Regression (3)
Logistic
Regression (5)

Model
Score

Error
%

3

6.75

0.06

0.00

0.00

3

6.75

0.94

0.00

0.00

0.7480 Bleeding History
Bleeding History, Months,
0.8540 Warfarin

60.00

Bleeding History, Months,
0.8514 Warfarin, Stroke, CHF

5

6.71

Calibration
%

Sensitivity
%

7.55

1.78

PPV
%

AUC
Variables

Logistic
Regression (10)

0

7.03

16.70

2.37

26.67

0.8467

ATRIA (1)

4

6.67

0.11

0.00

0.00

0.5551

ORBIT (1)

7

6.47

12.48

4.19

77.78

0.7453

HAS-BLED (1)

2

6.67

3.74

0.00

0.00

0.7323

QBLEED (22)

3

43.95

40.70

56.21

8.47

0.5764
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Bleeding History, Months,
Warfarin, Stroke, CHF, CKD,
Count Meds, Disability, White
Race, Low Platelets
Age > 65, Congestive Heart
Failure, Diabetes, Female
Gender, History of stroke,
Hypertension, Liver or renal
disease
Age > 75, Anemia, Non-aspirin
antiplatelet medication, History
of bleeding, Liver or renal
disease
Age > 65, Alcohol use/abuse,
Drug use/abuse, History of
bleeding, History of stroke,
Hypertension, Liver or renal
disease, TTIR < 60%
Age, Alcohol use/abuse,
Antidepressants, Non-aspirin
antiplatelet medication, Atrial
fibrillation, Cancer,
Carbamazepine or Phenytoin
prescription, CHF, Steroids,
Ethnicity, History of Bleeding,
Hypertension, Liver or renal
disease, Low platelet count,
NSAIDS, Smoker, Venous
thromboembolism, Townsend
score

Lasso (5)
Elastic Net (34)
Adaboost (34)
CART (34)
Model Results
Color Key:

2
0
0
3

6.75
6.75
6.79
7.27
Best
(3 points)

0.36
3.23
13.78
12.78
2nd
(2 points)

0.00
0.00
0.00
14.20

0.00
0.00
0.00
39.34

0.8481
0.8274
0.8273
0.8155

Bleeding History, Months,
Warfarin, Stroke, CHF
All
All
All

3rd
(1 point)

Table 4.4. Odds Ratios and Confidence Intervals for Logistic Regression Model with Subset of
Best 5 Variables.
Variable
Stroke
Bleeding
History
Months
Warfarin
CHF

Odds
Ratio

Conf Int Conf Int
(2.50%) (97.50%)
1.77
1.20
2.57

41.11
0.94
5.87
1.53

17.25
0.93
3.38
1.08

134.25
0.96
10.97
2.17
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Chapter 5
Discussion

5.1

Overview of the Dissertation
The three retrospective cohort studies conducted for this dissertation were designed to

explore the relationship between OAC prescription and gastrointestinal or intracranial bleeding
among older veterans. Using electronic health record data from the Veterans Health
Administration combined with American Community Survey and National Center for Health
Statistics data, a cohort of 130,750 Veterans age 50 to 89 were followed from October 1, 2010
until September 30, 2015 to compare cumulative incidence, incidence rates, and odds of
gastrointestinal and intracranial bleeding between veterans prescribed no OACs, warfarin, and
DOACs (dabigatran, rivaroxaban, or apixaban) (Chapter 2). A subset of 5,010 subjects from the
cohort with a prescription for warfarin or DOACs was further analyzed to identify risk factors
and determine the relationship between OAC prescription and bleeding events over time using
time-to-event analysis (Chapter 3). Predictive models were then developed using traditional and
machine learning methods for the subset of 5,010 subjects with a prescription for warfarin or
DOACs to discover a model for predicting risk of gastrointestinal or intracranial bleeding that
could be easily replicated by either VA or non-VA healthcare facilities (Chapter 4). This final
chapter of the dissertation will synthesize and summarize the findings from the three studies
presented in Chapters 2, 3, and 4, discuss the public health and policy impacts of the findings
from these three studies, and make recommendations for future research.
5.2

Summary of Findings

5.2.a Chapter 2 – Incidence and Odds of Gastrointestinal and Intracranial Bleeding

81

The objectives of the study presented in Chapter 2 were to describe and compare the
cumulative incidence, incidence rate, and odds of gastrointestinal and intracranial bleeding in
veterans age 50 to 89 who were prescribed warfarin, DOACs, or no OACs. Two analysis
approaches were employed: (1) a 5-day blackout period between OAC prescription date and
counting a bleeding event toward the outcome, and (2) no blackout period, meaning a bleeding
event at any time after OAC prescription would count as an outcome.
This study found that veterans who were not prescribed OACs experienced an average of
9 to 10 times the number of gastrointestinal bleeding events, and an average of 7 to 8 times the
number of intracranial bleeding events as would be expected in the general population. Using
both the no blackout and 5-day blackout period approaches this study found lower incidence
rates per 100 person-years for gastrointestinal and intracranial bleeding among veterans
prescribed OACs than previous studies on both veterans and non-veterans.14,27,56 This study also
found lower odds of bleeding among veterans prescribed an OAC than previous studies;9 this
was the case regardless of approach.
An important finding of the study presented in Chapter 2 was the difference in results
between the no blackout and the 5-day blackout period approaches. A better approach may be a
hybrid of the two compared here: to use no blackout period for subjects prescribed DOACs, and
a 5-day blackout period for subjects prescribed warfarin. Approached in this way, the findings
suggest subjects prescribed DOACs had comparable rates per 100 person-years for both
gastrointestinal and intracranial bleeding to subjects prescribed warfarin using a 5-day blackout
period.
Overall the findings of the study presented in Chapter 2 suggest that the approach used to
determine when a bleeding event should count as an outcome following OAC prescription will
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have a statistically significant effect on findings. There is no established body of research that
helps to explain the high cumulative incidence of gastrointestinal and intracranial bleeding
among veterans not prescribed OACs. One possible explanation is the increased number of
chronic conditions found in the veteran population. Another could be the use of blood thinning
medications prescribed outside the VA system or over-the-counter medication use (such as
aspirin) not captured in the VA EHR.
Both hypotheses associated with the aim of this study were disproved:
(1) Hypothesis – cumulative incidence and incidence rates of gastrointestinal and
intracranial bleeding will be comparable to previous studies.
a. Finding – cumulative incidence among subjects not prescribed OACs
was higher, and incidence rates were lower among subjects prescribed
warfarin or DOACs in this cohort than in previous studies.
(2) Hypothesis – cumulative incidence and incidence rates of gastrointestinal and
intracranial bleeding will be higher among subjects prescribed DOACs
compared to those prescribed warfarin.
a. Finding – cumulative incidence and incidence rates of gastrointestinal
and intracranial bleeding were higher among subjects prescribed
warfarin than those prescribed DOACs using both approaches. A
hybrid approach suggests incidence would be comparable between
warfarin and DOACs.
5.2.b Chapter 3 – Bleeding Risk Factors and Time-to-Event Analysis
The objectives of the study presented in Chapter 3 were to identify risk factors for
gastrointestinal and intracranial bleeding among older veterans prescribed OACs, and to
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calculate the relative risk of bleeding over time through time-to-event analysis. This study found
that as the time from OAC prescription increased, the proportion of veterans age 50 and older
who did not experience a gastrointestinal or intracranial bleeding event after being prescribed
warfarin was similar to those prescribed DOACs in the first eight months after prescription, but
those prescribed warfarin experienced slightly more bleeding from month nine through the end
of the study period. Findings were similar but slightly more divergent among veterans with a
diagnosis of atrial fibrillation. This finding was reversed in subjects age 75 or older at 7 through
12 and 36 months after prescription, where the proportion of subjects who did not experience a
bleeding event was slightly lower for those prescribed warfarin compared to those prescribed
DOACs. These differences were small and not statistically significant.
This study also found that prescriptions for antidepressants (HR = 1.35, 95% CI = 1.07,
1.70) or statins (HR = 1.31, 95% CI = 1.05, 1.63) were the strongest risk factors for
gastrointestinal or intracranial bleeding for all subjects, while history of bleeding was the
strongest risk factor for subjects with a diagnosis of atrial fibrillation (HR = 37.89, 95% CI =
15.56, 92.25) and for subjects age 75 or older (HR = 21.15, 95% CI = 7.93, 56.45).
Both hypotheses associated with the aim of this study were disproved:
(1) Hypothesis – variables estimating socioeconomic deprivation – Townsend
score and median household income by Zip code – will be significant risk
factors for gastrointestinal and intracranial bleeding.
a. Finding – variables estimating socioeconomic deprivation were not
significant risk factors in any of the time-to event models included in
this study.
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(2) Hypothesis – being prescribed an OAC for a longer period of time will be
associated with increased risk of gastrointestinal or intracranial bleeding.
a. Finding – time-to-event estimates found no statistically significant
difference in bleeding events as observation time in the study
increased.
5.2.c

Chapter 4 – Predicting Bleeding Risk
The objectives of the study presented in Chapter 4 were to develop and compare models

to predict gastrointestinal and intracranial bleeding among veterans age 50 to 89 who were
prescribed warfarin or DOACs using traditional and machine learning methods.
Twelve models were developed and evaluated. This study found that a logistic regression
model using the traditional ORBIT algorithm33 performed the best overall and had an AUC of
0.75. A logistic regression model with a best subset of five variables algorithm performed second
best, and had an AUC of 0.85. Two machine learning algorithms also performed fairly well in
predicting bleeding risk: a lasso model with an AUC of 0.85, and a CART model with an AUC
of 0.82. Overall model performance was based on five unweighted performance measures. This
study compared HAS-BLED, ATRIA, ORBIT, and QBLEED to logistic regression and machine
learning predictive models and found a model using the ORBIT score performed best, and with a
higher AUC than that found in previously published studies.
Both hypotheses associated with the aim of this study were disproved:
(1) Hypothesis – one or more algorithms produced using Machine Learning will
accurately predict gastrointestinal and intracranial bleeding, with a sensitivity
of 80% or greater and a positive predictive value of 75% or greater.
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a. Finding – none of the models evaluated had a sensitivity of 80% or
greater, and only the ORBIT model had a positive predictive value of
75% or greater, at 78%.
(2) Hypothesis – machine learning algorithms will perform better than the
traditional algorithms to which they are compared (HAS-BLED, ATRIA,
ORBIT, and QBLEED) at predicting risk of gastrointestinal and intracranial
bleeding.
a. Finding – a traditional algorithm (ORBIT) using logistic regression
performed better than the machine learning algorithms to which it was
compared. A logistic regression model with a subset of 5 variables
performed second best.
5.3

Limitations
The three studies presented in this dissertation had several limitations. The primary

source of data used in these studies came from a VA clinical and administrative database of
electronic health record data, and did not include non-VA claims or pharmacy benefit data, so
services and prescriptions obtained outside the VA healthcare system were not included.
Secondary data sources included American Community Survey and National Center for Health
Statistics data at the Zip code- and county-level, which may not have been applicable to every
subject in the study equally.
Subjects included in these studies were chosen based on outpatient utilization rather than
on hospitalization and subsequent OAC prescription. It is possible that using a posthospitalization cohort would have yielded different results, or that the risks of recently
discharged patients differ from those who have not been recently hospitalized. The subjects in
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the study cohort were overwhelmingly male; veterans as a population have higher proportions of
older white males with more comorbid conditions than the general population,8 so it’s uncertain
how applicable findings from these three studies are to female veterans and to non-veterans. The
subjects included in these studies primarily lived in New York and New Jersey, and regional
differences in demographics may limit the generalizability of findings to other states or regions
of the U.S. Subjects were not matched by propensity score or diagnosis-related groups across
OAC categories, and it’s possible that this kind of matching would have had an impact on
findings. Also, bleeding events were not categorized according to clinical significance, or
excluded for being minor or clinically insignificant.
None of the studies presented here examined the relationship between gastrointestinal
and intracranial bleeding and different OAC doses, changes in dose, or changes from one OAC
to another. The study presented in Chapter 2 only examined the impact of two different blackout
periods between first OAC prescription and subsequent bleeding events, and it is possible that
other blackout periods could result in different findings. The study presented in Chapter 3 did not
compare time-to-event between warfarin and each DOAC (dabigatran, rivaroxaban, and
apixaban) separately, which could have identified key differences between the three DOACs
included in the study. Also, this study included subjects with a variety of diagnoses that are
common indications for OAC prescription. In future research it will be important to include
comparisons of each DOAC with warfarin, and to analyze subpopulations with specific
diagnoses, because recent studies have found differences in outcomes in both of these areas,96,98
though these studies did not focus on veterans.
The study presented in Chapter 4 utilized minimal data preprocessing (such as centering,
scaling, imputation, and resampling) and no model tuning prior to training the 12 predictive
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models that were compared. It is possible that structuring variables in different ways – as
categorical, changing the number of categories, binary, continuous – and the use of tuning
techniques such as cross-validation could change the outcome of different models. This study
split the data 50/50 for training and validation, in order to distribute the outcome evenly for
model learning. It is possible that different data splits could change the results of the models.
Machine learning tools perform better with larger datasets,44 and the datasets used for the study
in Chapter 4 had 2,505 subjects each (training and validation), but machine learning algorithms
improve with increasing amounts of data so it is possible the machine learning algorithms used
in this study would have performed better with larger datasets. Finally, this study focused heavily
on logistic regression and machine learning variants of logistic regression, and it is possible that
other machine learning algorithms for classification, such as support vector machine, k-nearest
neighbors, or discriminant analysis would have performed differently or better.
5.4

Synthesis and Implications
Because the three studies presented in this dissertation were designed to build on one

another, and two of the studies used a subset of the cohort, there were no findings that were
applicable across all three studies. Several findings from the studies presented in this dissertation
were consistent with previous research:
•
•

•

Subjects prescribed warfarin experienced bleeding in the first 30 days following
prescription, while those prescribed DOACs did not.
Subjects prescribed warfarin experienced bleeding sooner than those prescribed DOACs,
except in subjects age 75 or older this finding was reversed – though this finding was not
statistically significant.
A prescription for antidepressants, a prescription for statins, and a history of bleeding
were the strongest risk factors associated with gastrointestinal and intracranial bleeding.

Other findings contradicted previous research:
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•
•

Incidence rates and odds of gastrointestinal and intracranial bleeding were lower in this
study cohort than those found in previous studies.
Townsend score and many other variables identified as significant risk factors in other
study populations were not significant risk factors in this cohort of older veterans.

And some findings did not have any previous studies to which they could be compared:
•
•

•

The use of different blackout periods in determining whether to count an event as an
outcome had a significant impact on results.
Veterans in the study cohort who were not prescribed OACs had gastrointestinal bleeding
that was 9-10 times higher and intracranial bleeding that was 7-8 times higher than what
would be expected in the general population.
A predictive model using a traditional algorithm (ORBIT) and logistic regression
performed better than other traditional algorithms (HAS-BLED and ATRIA), time-toevent (QBLEED), and machine learning models in predicting gastrointestinal and
intracranial bleeding risk.
The studies presented in this dissertation contribute to the body of research knowledge

about veterans and gastrointestinal and intracranial bleeding following OAC prescription. These
studies aimed to help healthcare organizations meet the goals set forth in the National Action
Plan for Adverse Drug Event Prevention,4 and The Joint Commission Patient Safety Goals,37 as
well as assist VA healthcare facilities comply with the VHA Policy for Anticoagulation Therapy
Management.40 The ORBIT algorithm,33 a set of five variables readily available in electronic
health record data, results in a score that can be used in a logistic regression model to assign
predicted bleeding risk to patients prescribed OACs. A simpler intervention without the use of
predictive models could target those with a history of bleeding who are prescribed OACs, based
on the strength of this single predictor.
5.5

Conclusion and Recommendations for Future Research
The challenge of minimizing gastrointestinal and intracranial bleeding following OAC

prescription is on-going, and while the studies presented in this dissertation shed light on some
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areas regarding older veterans and risk of gastrointestinal and intracranial bleeding, there is still a
need for more research. Potential future research topics include:
•

•
•

Investigation into the higher occurrence of gastrointestinal and intracranial bleeding
among older veterans not prescribed OACs, and how much of this increase can be
explained by a higher disease burden in veterans.
Research to uncover why bleeding incidence rates among older veterans prescribed
OACs were lower than previous research in non-veterans.
Investigation of different machine learning algorithms to predict bleeding risk.

The greatest gains in preventing ADEs will likely be realized with increased sharing and use of
electronic health data, and the ability to discover predictive models that perform well on a variety
of evaluation measures, and then to refine these models as the number of events decrease over
time.
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Appendix 1. List of ICD-9 and ICD-10 Codes for Gastrointestinal and Intracranial Bleeding as
an Outcome.
ICD-9 Code
455.2
455.5
456.0
456.20
530.7
530.82
531.00
531.10
531.20
531.40
531.50
531.60
532.00
532.10
532.20
532.40
532.50
532.60
533.00
533.10
533.20
533.40
533.50
533.60
534.00
534.10
534.20
534.40
534.50
534.60
535.01
535.11
535.21
535.31
535.41
535.51
535.61

ICD-9 Description
Other hemorrhoids
Residual hemorrhoidal skin tags
Esophageal varices with bleeding
Secondary esophageal varices with bleeding
Gastro-esophageal laceration-bleed syndrome
Other specified diseases of esophagus
Gastric ulcer - Acute with bleed
Gastric ulcer - Acute with perforation
Gastric ulcer - Acute with both bleed and perforation
Gastric ulcer - Chronic or unspecified with bleed
Gastric ulcer - Chronic or unspecified with perforation
Gastric ulcer - Chronic or unspecified with both bleed and perforation
Duodenal ulcer - Acute with bleed
Duodenal ulcer - Acute with perforation
Duodenal ulcer - Acute with both bleed and perforation
Duodenal ulcer - Chronic or unspecified with bleed
Duodenal ulcer - Chronic or unspecified with perforation
Duodenal ulcer - Chronic or unspecified with both bleed and perforation
Peptic ulcer, site unspecified - Acute with bleed
Peptic ulcer, site unspecified - Acute with perforation
Peptic ulcer, site unspecified - Acute with both bleed and perforation
Peptic ulcer, site unspecified - Chronic or unspecified with bleed
Peptic ulcer, site unspecified - Chronic or unspecified with perforation
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and
perforation
Gastrojejunal ulcer - Acute with bleed
Gastrojejunal ulcer - Acute with perforation
Gastrojejunal ulcer - Acute with both bleed and perforation
Gastrojejunal ulcer - Chronic or unspecified with bleed
Gastrojejunal ulcer - Chronic or unspecified with perforation
Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation
Acute haemorrhagic gastritis
Atrophic gastritis with hemorrhage
Gastric mucosal hypertrophy with hemorrhage
Alcoholic gastritis with hemorrhage
Other specified gastritis with hemorrhage
Unspecified gastritis and gastroduodenitis with hemorrhage
Duodenitis with hemorrhage
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537.83
562.02
562.03
562.12
562.13
568.81
569.3
569.85
569.86
578.0
578.1
578.9
430
431
432
432.1
432.9
438.9

Angiodysplasia of stomach and duodenum with hemorrhage
Diverticulosis of small intestine with hemorrhage
Diverticulitis of small intestine with hemorrhage
Diverticulosis of colon with hemorrhage hemorrhage
Diverticulitis of small intestine with hemorrhage
Hemoperitoneum
Hemorrhage of rectum and anus
Angiodysplasia of intestine with hemorrhage
Dieulafoy lesion (hemorrhagic) of intestine
Hematemesis
Melena
Gastrointestinal bleed, unspecified
Subarachnoid bleed
Intracerebral bleed
Other nontraumatic intracranial bleed
Subdural bleed (acute)(nontraumatic)
Intracranial bleed (nontraumatic), unspecified
Unspecified sequelae of nontraumatic subarachnoid hemorrhage

800.30

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with state of consciousness unspecified

800.31

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with no loss of consciousness

800.32

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with brief (less than 1 hour) loss of consciousness

800.33

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with moderate (1-24 hours) loss of consciousness

800.34

800.35
800.36
800.39
997.02
ICD-10
CODE
I85.0
I85.11
K22.6
K22.8

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with prolonged (more than 24 hours) loss of consciousness
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with prolonged (more than 24 hours) loss of consciousness without returning to
previous existing conscious level
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with loss of consciousness of unspecified duration
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with concussion
Iatrogenic cerebrovascular infarction or hemorrhage
ICD-10 CODE DESCRIPTION
Esophageal varices with bleeding
Secondary esophageal varices with bleeding
Gastro-esophageal laceration-bleed syndrome
Other specified diseases of esophagus
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K25.0
K25.1
K25.2
K25.4
K25.5
K25.6
K26.0
K26.1
K26.2
K26.4
K26.5
K26.6
K27.0
K27.1
K27.2
K27.4
K27.5
K27.6
K28.0
K28.1
K28.2
K28.4
K28.5
K28.6
K29.0
K29.21
K29.41
K29.51
K29.61
K29.71
K29.81
K29.91
K318.11
K55.21
K57.11
K57.13
K57.31
K57.33
K62.5
K64.4
K64.8

Acute gastric ulcer with hemorrhage
Gastric ulcer - Acute with perforation
Gastric ulcer - Acute with both bleed and perforation
Gastric ulcer - Chronic or unspecified with bleed
Gastric ulcer - Chronic or unspecified with perforation
Gastric ulcer - Chronic or unspecified with both bleed and perforation
Duodenal ulcer - Acute with bleed
Duodenal ulcer - Acute with perforation
Duodenal ulcer - Acute with both bleed and perforation
Duodenal ulcer - Chronic or unspecified with bleed
Duodenal ulcer - Chronic or unspecified with perforation
Duodenal ulcer - Chronic or unspecified with both bleed and perforation
Peptic ulcer, site unspecified - Acute with bleed
Peptic ulcer, site unspecified - Acute with perforation
Peptic ulcer, site unspecified - Acute with both bleed and perforation
Peptic ulcer, site unspecified - Chronic or unspecified with bleed
Peptic ulcer, site unspecified - Chronic or unspecified with perforation
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and
perforation
Gastrojejunal ulcer - Acute with bleed
Gastrojejunal ulcer - Acute with perforation
Gastrojejunal ulcer - Acute with both bleed and perforation
Gastrojejunal ulcer - Chronic or unspecified with bleed
Gastrojejunal ulcer - Chronic or unspecified with perforation
Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation
Acute haemorrhagic gastritis
Alcoholic gastritis with hemorrhage
Atrophic gastritis with hemorrhage
Unspecified chronic gastritis with bleeding
Gastric mucosal hypertrophy with hemorrhage
Unspecified gastritis and gastroduodenitis with hemorrhage
Duodenitis with hemorrhage
Gastroduodenitis with bleeding
Angiodysplasia of stomach and duodenum with hemorrhage
Angiodysplasia of intestine with hemorrhage
Diverticulosis of small intestine with hemorrhage
Diverticulitis of small intestine with hemorrhage
Diverticulosis of colon with hemorrhage hemorrhage
Diverticulitis of small intestine with hemorrhage
Hemorrhage of rectum and anus
Residual hemorrhoidal skin tags
Other hemorrhoids
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K66.1

Hemoperitoneum

K91.61

Intraoperative hemorrhage and hematoma of a digestive system organ or
structure complicating a digestive sytem procedure

K91.62
K92.0
K92.1
K92.2
K94.01
K94.11
K94.21
K94.31
I60.00
I60.01
I60.02
I60.10
I60.11
I60.12
I60.20
I60.21
I60.22
I60.30
I60.31
I60.32
I60.40
I60.50
I60.51
I60.52
I60.6
I60.7
I60.8
I60.9
I61.0
I61.1
I61.2
I61.3
I61.4

Intraoperative hemorrhage and hematoma of a digestive system organ or
structure complicating other procedure
Hematemesis
Melena
Gastrointestinal bleed, unspecified
Colostomy hemorrhage
Enterostomy hemorrhage
Gastrostomy hemorrhage
Esophagostomy hemorrhage
Subarachnoid bleed from carotid siphon and bifurcation
Nontraumatic subarachnoid hemorrhage from right carotid siphon and
bifurcation
Nontraumatic subarachnoid hemorrhage from left carotid siphon and
bifurcation
Subarachnoid bleed from middle cerebral artery
Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
Subarachnoid bleed from anterior communicating artery
Nontraumatic subarachnoid hemorrhage from right anterior communicating
artery
Nontraumatic subarachnoid hemorrhage from left anterior communicating
artery
Subarachnoid bleed from posterior communicating artery
Nontraumatic subarachnoid hemorrhage from right posterior communicating
artery
Nontraumatic subarachnoid hemorrhage from left posterior communicating
artery
Subarachnoid bleed from basilar artery
Subarachnoid bleed from vertebral artery
Nontraumatic subarachnoid hemorrhage from right vertebral artery
Nontraumatic subarachnoid hemorrhage from left vertebral artery
Subarachnoid bleed from other intracranial arteries
Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
Other nontraumatic subarachnoid hemorrhage
Nontraumatic subarachnoid hemorrhage, unspecified
Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
Intracerebral bleed in hemisphere, cortical
Intracerebral bleed in hemisphere, unspecified
Intracerebral bleed in brain stem
Intracerebral bleed in cerebellum
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I61.5
I61.6
I61.8
I61.9
I62.00
I62.01
I62.02
I62.03
I62.1
I62.9
I69.00
I69.10
I69.20
S064-066

Intracerebral bleed, intraventricular
Intracerebral bleed, multiple localized
Other intracerebral bleed
Intracerebral bleed, unspecified
Nontraumatic subdural hemorrhage, unspecified
Nontraumatic acute subdural hemorrhage
Nontraumatic subacute subdural hemorrhage
Nontraumatic chronic subdural hemorrhage
Nontraumatic extradural hemorrhage
Nontraumatic intracranial hemorrhage, unspecified
Unspecified sequelae of nontraumatic subarachnoid hemorrhage
Unspecified sequelae of nontraumatic intracerebral hemorrhage
Unspecified sequelae of other nontraumatic intracranial hemorrhage
Traumatic intracranial hemorrhage with LOC
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Appendix 2. List of ICD-9 and ICD-10 Codes for History of Bleeding Covariate.
ICD-9 Code
078.6
246.3
252.8
280.0
285.1
286.52
286.59
286.6
286.9
287.30
287.39
287.49
287.8
287.9
360.43
362.43
362.81
363.61
363.62
363.72
364.41
372.72
374.81
376.32
377.42
379.23
423.0
430
431
432
432.1
432.9
438.9
455.2
455.5
456.0
456.20

ICD-9 Description
Hemorrhagic nephrosonephritis
Hemorrhage and infarction of thyroid
Other specified disorders of parathyroid gland
Iron deficiency anemia secondary to blood loss (chronic)
Acute posthemorrhagic anemia
Acquired hemophilia
Other hemorrhagic disorder due to intrinsic circulating anticoagulants,
antibodies, or inhibitors
Defibrination syndrome
Other and unspecified coagulation defects
Primary thrombocytopenia, unspecified
Other primary thrombocytopenia
Other secondary thrombocytopenia
Other specified hemorrhagic conditions
Unspecified hemorrhagic conditions
Hemophthalmos except current injury
Hemorrhagic detach of retinal pigment epithelium
Retinal hemorrhage
Choroidal hemorrhage unspecified
Expulsive choroidal hemorrhage
Hemorrhagic choroidal detach
Hyphema of iris and ciliary body
Conjunctival hemorrhage
Hemorrhage of eyelid
Orbital hemorrhage
Hemorrhage in optic nerve sheaths
Vitreous hemorrhage
Hemopericardium
Subarachnoid bleed
Intracerebral bleed
Other nontraumatic intracranial bleed
Subdural bleed (acute)(nontraumatic)
Intracranial bleed (nontraumatic), unspecified
Unspecified sequelae of nontraumatic subarachnoid hemorrhage
Other hemorrhoids
Residual hemorrhoidal skin tags
Esophageal varices with bleeding
Secondary esophageal varices with bleeding
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459.0
511.89
530.7
530.82
531.00
531.10
531.20
531.40
531.50
531.60
532.00
532.10
532.20
532.40
532.50
532.60
533.00
533.10
533.20
533.40
533.50
533.60
534.00
534.10
534.20
534.40
534.50
534.60
535.01
535.11
535.21
535.31
535.41
535.51
535.61
537.83
562.02
562.03
562.12
562.13
568.81

Hemorrhage unspecified
Hemothorax
Gastro-esophageal laceration-bleed syndrome
Other specified diseases of esophagus
Gastric ulcer - Acute with bleed
Gastric ulcer - Acute with perforation
Gastric ulcer - Acute with both bleed and perforation
Gastric ulcer - Chronic or unspecified with bleed
Gastric ulcer - Chronic or unspecified with perforation
Gastric ulcer - Chronic or unspecified with both bleed and perforation
Duodenal ulcer - Acute with bleed
Duodenal ulcer - Acute with perforation
Duodenal ulcer - Acute with both bleed and perforation
Duodenal ulcer - Chronic or unspecified with bleed
Duodenal ulcer - Chronic or unspecified with perforation
Duodenal ulcer - Chronic or unspecified with both bleed and perforation
Peptic ulcer, site unspecified - Acute with bleed
Peptic ulcer, site unspecified - Acute with perforation
Peptic ulcer, site unspecified - Acute with both bleed and perforation
Peptic ulcer, site unspecified - Chronic or unspecified with bleed
Peptic ulcer, site unspecified - Chronic or unspecified with perforation
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and
perforation
Gastrojejunal ulcer - Acute with bleed
Gastrojejunal ulcer - Acute with perforation
Gastrojejunal ulcer - Acute with both bleed and perforation
Gastrojejunal ulcer - Chronic or unspecified with bleed
Gastrojejunal ulcer - Chronic or unspecified with perforation
Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation
Acute haemorrhagic gastritis
Atrophic gastritis with hemorrhage
Gastric mucosal hypertrophy with hemorrhage
Alcoholic gastritis with hemorrhage
Other specified gastritis with hemorrhage
Unspecified gastritis and gastroduodenitis with hemorrhage
Duodenitis with hemorrhage
Angiodysplasia of stomach and duodenum with hemorrhage
Diverticulosis of small intestine with hemorrhage
Diverticulitis of small intestine with hemorrhage
Diverticulosis of colon with hemorrhage hemorrhage
Diverticulitis of small intestine with hemorrhage
Hemoperitoneum
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569.3
569.85
569.86
578.0
578.1
578.9
596.7
596.89
599.70
599.71
599.72
602.1
620.1
620.8
621.4
622.8
623.8
626.2
626.4
626.5
626.6
626.7
626.8
626.9
627.0
627.1
719.10
719.11
719.12
719.13
719.14
719.15
719.16
719.17
719.18
719.19
782.7
784.7
784.8
786.30
786.39

Hemorrhage of rectum and anus
Angiodysplasia of intestine with hemorrhage
Dieulafoy lesion (hemorrhagic) of intestine
Hematemesis
Melena
Gastrointestinal bleed, unspecified
Hemorrhage into bladder wall
Other specified disorders of bladder
Hematuria, unspecified
Gross hematuria
Other microscopic hematuria
Congestion or hemorrhage of prostate
Corpusluteum cyst or hematoma
Other noninflammatory disorders of ovary, fallopian tube, and broad ligament
Hematometra
Other specified noninflammatory disorders of cervix
Other specified noninflammatory disorders of vagina
Excessive or frequent menstruation
Irregular menstrual cycle
Ovulation bleeding
Metrorrhagia
Postcoital bleeding
Other disorders of menstruation and other abnormal bleeding
Unspecified disorders of menstruation and other abnormal bleeding
Premenopausal menorrhagia
Postmenopausal bleeding
Hemarthrosis site unspecified
Herarthrosis involving shoulder region
Herarthrosis involving upper arm
Herarthrosis involving forearm
Herarthrosis involving hand
Herarthrosis involving pelvic region and thigh
Herarthrosis involving lower leg
Herarthrosis involving ankle and foot
Herarthrosis involving other specified sites
Herarthrosis involving multiple sites
Spontaneous ecchymoses
Epistaxis
Hemorrhage from throat
Hemoptysis
Hemorrhage from other sites in respiratory passages
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800.30

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with state of consciousness unspecified

800.31

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with no loss of consciousness

800.32

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with brief (less than 1 hour) loss of consciousness

800.33

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with moderate (1-24 hours) loss of consciousness

800.34

800.35
800.36
800.39
860.2
860.3
997.02
998.11
ICD-10
CODE
D50.0
D62

Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with prolonged (more than 24 hours) loss of consciousness
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with prolonged (more than 24 hours) loss of consciousness without returning to
previous existing conscious level
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with loss of consciousness of unspecified duration
Closed fracture of vault of skull with other unspecified intracranial hemorrhage
with concussion
Traumatic hemothorax with open wound into thorax
Traumatic hemothorax without open wound into thorax
Iatrogenic cerebrovascular infarction or hemorrhage
Hemorrhage complicating a procedure

D78.02

ICD-10 CODE DESCRIPTION
Iron deficiency anemia secondary to blood loss (chronic)
Acute posthemorrhagic anemia
Intraoperative hemorrhage and hematoma of the spleen complicating a
procedure on the spleen
Intraoperative hemorrhage and hematoma of the spleen complicating other
procedure

E36.01

Intraoperative hemorrhage and hematoma of an endocrine system organ or
structure complicating an endocrine system procedure

E36.02

Intraoperative hemorrhage and hematoma of an endocrine system organ or
structure complicating other procedure

G97.31

Intraoperative hemorrhage and hematoma of a nervous system organ or
structure complicating a nervous system procedure

G97.32
H05.231
H05.232
H05.233
H05.239
H11.30
H11.31

Intraoperative hemorrhage and hematoma of a nervous system organ or
structure complicating other procedure
Hemorrhage of right orbit
Hemorrhage of left orbit
Hemorrhage of bilateral orbit
Hemorrhage of unspecified orbit
Conjunctival hemorrhage, unspecified eye
Conjunctival hemorrhage, right eye

D78.01
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H11.32
H11.33
H31.301
H31.302
H31.303
H31.309
H31.311
H31.312
H31.313
H31.319
H35.60
H35.61
H35.62
H35.63
H43.10
H43.11
H43.12
H43.13
H47.021
H47.022
H47.023
H47.029

Conjunctival hemorrhage, left eye
Conjunctival hemorrhage, bilateral
Unspecified choroidal hemorrhage, right eye
Unspecified choroidal hemorrhage, left eye
Unspecified choroidal hemorrhage, bilateral
Unspecified choroidal hemorrhage, unspecified eye
Expulsive choroidal hemorrhage, right eye
Expulsive choroidal hemorrhage, left eye
Expulsive choroidal hemorrhage, bilateral
Expulsive choroidal hemorrhage, unspecified eye
Retinal hemorrhage, unspecified eye
Retinal hemorrhage, right eye
Retinal hemorrhage, left eye
Retinal hemorrhage, bilateral
Vitreous hemorrhage, unspecified eye
Vitreous hemorrhage, right eye
Vitreous hemorrhage, left eye
Vitreous hemorrhage, bilateral
Hemorrhage in optic nerve sheath, right eye
Hemorrhage in optic nerve sheath, left eye
Hemorrhage in optic nerve sheath, bilateral
Hemorrhage in optic nerve sheath, unspecified eye

H59.111

Intraoperative hemorrhage and hematoma of right eye and adnexa complicating
an ophthalmic procedure

H59.112

Intraoperative hemorrhage and hematoma of left eye and adnexa complicating
an ophthalmic procedure

H59.113

Intraoperative hemorrhage and hematoma of eye and adnexa complicating an
ophthalmic procedure, bilateral

H59.122

Intraoperative hemorrhage and hematoma of unspecified eye and adnexa
complicating an ophthalmic procedure
Intraoperative hemorrhage and hematoma of right eye and adnexa complicating
other procedure
Intraoperative hemorrhage and hematoma of left eye and adnexa complicating
other procedure

H59.123

Intraoperative hemorrhage and hematoma of eye and adnexa complicating
other procedure, bilateral

H59.129

Intraoperative hemorrhage and hematoma of unspecified eye and adnexa
complicating other procedure

H95.21

Intraoperative hemorrhage and hematoma of ear and mastoid process
complicating a procedure on the ear and mastoid process

H95.22

Intraoperative hemorrhage and hematoma of ear and mastoid process
complicating other procedure

H59.119
H59.121
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I60.00
I60.01
I60.02
I60.10
I60.11
I60.12
I60.20
I60.21
I60.22
I60.30
I60.31
I60.32
I60.40
I60.50
I60.51
I60.52
I60.6
I60.7
I60.8
I60.9
I61.0
I61.1
I61.2
I61.3
I61.4
I61.5
I61.6
I61.8
I61.9
I62.00
I62.01
I62.02
I62.03
I62.1
I62.9
I69.00
I69.10

Subarachnoid bleed from carotid siphon and bifurcation
Nontraumatic subarachnoid hemorrhage from right carotid siphon and
bifurcation
Nontraumatic subarachnoid hemorrhage from left carotid siphon and
bifurcation
Subarachnoid bleed from middle cerebral artery
Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
Subarachnoid bleed from anterior communicating artery
Nontraumatic subarachnoid hemorrhage from right anterior communicating
artery
Nontraumatic subarachnoid hemorrhage from left anterior communicating
artery
Subarachnoid bleed from posterior communicating artery
Nontraumatic subarachnoid hemorrhage from right posterior communicating
artery
Nontraumatic subarachnoid hemorrhage from left posterior communicating
artery
Subarachnoid bleed from basilar artery
Subarachnoid bleed from vertebral artery
Nontraumatic subarachnoid hemorrhage from right vertebral artery
Nontraumatic subarachnoid hemorrhage from left vertebral artery
Subarachnoid bleed from other intracranial arteries
Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
Other nontraumatic subarachnoid hemorrhage
Nontraumatic subarachnoid hemorrhage, unspecified
Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
Intracerebral bleed in hemisphere, cortical
Intracerebral bleed in hemisphere, unspecified
Intracerebral bleed in brain stem
Intracerebral bleed in cerebellum
Intracerebral bleed, intraventricular
Intracerebral bleed, multiple localized
Other intracerebral bleed
Intracerebral bleed, unspecified
Nontraumatic subdural hemorrhage, unspecified
Nontraumatic acute subdural hemorrhage
Nontraumatic subacute subdural hemorrhage
Nontraumatic chronic subdural hemorrhage
Nontraumatic extradural hemorrhage
Nontraumatic intracranial hemorrhage, unspecified
Unspecified sequelae of nontraumatic subarachnoid hemorrhage
Unspecified sequelae of nontraumatic intracerebral hemorrhage
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I69.20
I85.0
I85.11

Unspecified sequelae of other nontraumatic intracranial hemorrhage
Esophageal varices with bleeding
Secondary esophageal varices with bleeding

I97.410

Intraoperative hemorrhage and hematoma of a circulatory system organ or
structure complicating a cardiac catheterization

I97.411

Intraoperative hemorrhage and hematoma of a circulatory system organ or
structure complicating a cardiac bypass

I97.418

Intraoperative hemorrhage and hematoma of a circulatory system organ or
structure complicating other circulatory system procedure

I97.42
J94.2
J95.01

Intraoperative hemorrhage and hematoma of a circulatory system organ or
structure complicating other procedure
Hemothorax
Hemorrhage from tracheostomy stoma

J95.61

Intraoperative hemorrhage and hematoma of a respiratory system organ or
structure complicating a respiratory system procedure

J95.62
K22.6
K22.8
K25.0
K25.1
K25.2
K25.4
K25.5
K25.6
K26.0
K26.1
K26.2
K26.4
K26.5
K26.6
K27.0
K27.1
K27.2
K27.4
K27.5
K27.6
K28.0
K28.1
K28.2
K28.4

Intraoperative hemorrhage and hematoma of a respiratory system organ or
structure complicating other procedure
Gastro-esophageal laceration-bleed syndrome
Other specified diseases of esophagus
Acute gastric ulcer with hemorrhage
Gastric ulcer - Acute with perforation
Gastric ulcer - Acute with both bleed and perforation
Gastric ulcer - Chronic or unspecified with bleed
Gastric ulcer - Chronic or unspecified with perforation
Gastric ulcer - Chronic or unspecified with both bleed and perforation
Duodenal ulcer - Acute with bleed
Duodenal ulcer - Acute with perforation
Duodenal ulcer - Acute with both bleed and perforation
Duodenal ulcer - Chronic or unspecified with bleed
Duodenal ulcer - Chronic or unspecified with perforation
Duodenal ulcer - Chronic or unspecified with both bleed and perforation
Peptic ulcer, site unspecified - Acute with bleed
Peptic ulcer, site unspecified - Acute with perforation
Peptic ulcer, site unspecified - Acute with both bleed and perforation
Peptic ulcer, site unspecified - Chronic or unspecified with bleed
Peptic ulcer, site unspecified - Chronic or unspecified with perforation
Peptic ulcer, site unspecified - Chronic or unspecified with both bleed and
perforation
Gastrojejunal ulcer - Acute with bleed
Gastrojejunal ulcer - Acute with perforation
Gastrojejunal ulcer - Acute with both bleed and perforation
Gastrojejunal ulcer - Chronic or unspecified with bleed
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K28.5
K28.6
K29.0
K29.21
K29.41
K29.51
K29.61
K29.71
K29.81
K29.91
K318.11
K55.21
K57.11
K57.13
K57.31
K57.33
K62.5
K64.4
K64.8
K66.1

Gastrojejunal ulcer - Chronic or unspecified with perforation
Gastrojejunal ulcer - Chronic or unspecified with both bleed and perforation
Acute haemorrhagic gastritis
Alcoholic gastritis with hemorrhage
Atrophic gastritis with hemorrhage
Unspecified chronic gastritis with bleeding
Gastric mucosal hypertrophy with hemorrhage
Unspecified gastritis and gastroduodenitis with hemorrhage
Duodenitis with hemorrhage
Gastroduodenitis with bleeding
Angiodysplasia of stomach and duodenum with hemorrhage
Angiodysplasia of intestine with hemorrhage
Diverticulosis of small intestine with hemorrhage
Diverticulitis of small intestine with hemorrhage
Diverticulosis of colon with hemorrhage hemorrhage
Diverticulitis of small intestine with hemorrhage
Hemorrhage of rectum and anus
Residual hemorrhoidal skin tags
Other hemorrhoids
Hemoperitoneum

K91.61

Intraoperative hemorrhage and hematoma of a digestive system organ or
structure complicating a digestive sytem procedure

K91.62
K92.0
K92.1
K92.2
K94.01
K94.11
K94.21
K94.31

Intraoperative hemorrhage and hematoma of a digestive system organ or
structure complicating other procedure
Hematemesis
Melena
Gastrointestinal bleed, unspecified
Colostomy hemorrhage
Enterostomy hemorrhage
Gastrostomy hemorrhage
Esophagostomy hemorrhage

L76.01

Intraoperative hemorrhage and hematoma of skin and subcutaneous tissue
complicating a dermatologic procedure

L76.02

Intraoperative hemorrhage and hematoma of skin and subcutaneous tissue
complicating other procedure

M96.810

Intraoperative hemorrhage and hematoma of a musculoskeletal structure
complicating a musculoskeletal system procedure

M96.811
N02.0
N02.1

Intraoperative hemorrhage and hematoma of a musculoskeletal structure
complicating other procedure
Recurrent and persistent hematuria with minor glomerular abnormality
Recurrent and persistent hematuria with focal and segmental glomerular lesions
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N02.5
N02.6
N02.7
N02.8
N02.9
N42.1
N99.510
N99.520
N99.530

Recurrent and persistent hematuria with diffuse membraneous
glomerulonephritis
Recurrent and persistent hematuria with diffuse mesangial proliferative
glomerulonephritis
Recurrent and persistent hematuria with diffuse endocapillaryproliferative
glomerulonephritis
Recurrent and persistent hematuria with diffuse mesangiocapillary
glomerulonephritis
Recurrent and persistent hematuria with dense deposit disease
Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis
Recurrent and persistent hematuria with other morphologic changes
Recurrent and persistent hematuria with unspecified morphologic changes
Congestion and hemorrhage of prostate
Cystostomy hemorrhage
Hemorrhage of other external stoma of urinary tract
Hemorrhage of other stoma of urinary tract

N99.61

Intraoperative hemorrhage and hematoma of a genitourinary system organ or
structure complicating a genitourinary system procedure

N02.2
N02.3
N02.4

S06.4X2A

Intraoperative hemorrhage and hematoma of a genitourinary system organ or
structure complicating other procedure
Epistaxis
Hemorrhage from throat
Hemoptysis
Hemorrhage from other sites in respiratory passages
Hemorrhage from respiratory passages, unspecified
Gross hematuria
Benign essential microscopic hematuria
Other microscopic hematuria
Hematuria, unspecified
Hemorrhage, not elsewhere classified
Epidural hemorrhage without loss of consciousness, initial encounter
Epidural hemorrhage without loss of consciousness, subsequent encounter
Epidural hemorrhage without loss of consciousness, sequela
Epidural hemorrhage with loss of consciousness of 30 minutes or less, initial
encounter
Epidural hemorrhage with loss of consciousness of 30 minutes or less,
subsequent encounter
Epidural hemorrhage with loss of consciousness of 30 minutes or less, sequela
Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes,
initial encounter

S06.4X2D

Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes,
subsequent encounter

N99.62
R04.0
R04.1
R04.2
R04.89
R04.9
R31.0
R31.1
R31.2
R31.9
R58
S06.4X0A
S06.4X0D
S06.4X0S
S06.4X1A
S06.4X1D
S06.4X1S
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S06.4X2S
S06.4X3A

Epidural hemorrhage with loss of consciousness of 31 minutes to 59 minutes,
sequela
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59
minutes, initial encounter

S06.4X4D
S06.4X4S

Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59
minutes, subsequent encounter
Epidural hemorrhage with loss of consciousness of 1 hour to 5 hours 59
minutes, sequela
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, initial
encounter
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours,
subsequent encounter
Epidural hemorrhage with loss of consciousness of 6 hours to 24 hours, sequela

S06.4X5A

Epidural hemorrhage with loss of consciousness greater than 24 hours with
return to pre-existing conscious level, initial encounter

S06.4X5D

Epidural hemorrhage with loss of consciousness greater than 24 hours with
return to pre-existing conscious level, subsequent encounter

S06.4X5S

Epidural hemorrhage with loss of consciousness greater than 24 hours with
return to pre-existing conscious level, sequela

S06.4X3D
S06.4X3S
S06.4X4A

S06.4X6D

Epidural hemorrhage with loss of consciousness greater than 24 hours without
return to pre-existing conscious level with patient surviving, initial encounter
Epidural hemorrhage with loss of consciousness greater than 24 hours without
return to pre-existing conscious level with patient surviving, subsequent
encounter

S06.4X6S

Epidural hemorrhage with loss of consciousness greater than 24 hours without
return to pre-existing conscious level with patient surviving, sequela

S06.4X7A

Epidural hemorrhage with loss of consciousness of any duration with death due
to brain injury prior to regaining consciousness, initial encounter

S06.4X7D

Epidural hemorrhage with loss of consciousness of any duration with death due
to brain injury prior to regaining consciousness, subsequent encounter

S06.4X7S

Epidural hemorrhage with loss of consciousness of any duration with death due
to brain injury prior to regaining consciousness, sequela

S06.4X8A

Epidural hemorrhage with loss of consciousness of any duration with death due
to other causes prior to regaining consciousness, initial encounter

S06.4X8D

Epidural hemorrhage with loss of consciousness of any duration with death due
to other causes prior to regaining consciousness, subsequent encounter

S06.4X6A

S06.4X8S
S06.4X9A
S06.4X9D
S06.4X9S

Epidural hemorrhage with loss of consciousness of any duration with death due
to other causes prior to regaining consciousness, sequela
Epidural hemorrhage with loss of consciousness of unspecified duration, initial
encounter
Epidural hemorrhage with loss of consciousness of unspecified duration,
subsequent encounter
Epidural hemorrhage with loss of consciousness of unspecified duration,
sequela
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S064-066
T82.837A
T82.837D
T82.837S
T82.838A
T82.838D
T82.838S
T83.83XA
T83.83XD
T83.83XS

Traumatic intracranial hemorrhage with LOC
Hemorrhage of cardiac prosthetic devices, implants and grafts, initial encounter
Hemorrhage of cardiac prosthetic devices, implants and grafts, subsequent
encounter
Hemorrhage of cardiac prosthetic devices, implants and grafts, sequela
Hemorrhage of vascular prosthetic devices, implants and grafts, initial
encounter
Hemorrhage of vascular prosthetic devices, implants and grafts, subsequent
encounter
Hemorrhage of vascular prosthetic devices, implants and grafts, sequela
Hemorrhage of genitourinary prosthetic devices, implants and grafts, initial
encounter
Hemorrhage of genitourinary prosthetic devices, implants and grafts,
subsequent encounter
Hemorrhage of genitourinary prosthetic devices, implants and grafts, sequela
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Appendix 3. Decision Tree Model and Gains Tables.

Figure A.3.1. CART Machine Learning Algorithm Decision Tree Model.

Key: BleedingHx = bleeding history, OACCat = warfarin prescription, months = number of
months to bleeding outcome, medhhinc = median household income for Zip code of residence,
PctRural = percent of county considered rural, MaritalS = married.
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Table A.3.3. Lasso Machine Learning Model Variables and Odds Ratios.
Variable
Stroke
Bleeding History
Months to Bleeding Event
Warfarin
Congestive Heart Failure

Odds Ratio
1.10
6.10
0.97
1.48
1.42
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